AU2008218605A1 - Meganuclease variants cleaving a DNA target sequence from the beta-2-microglobulin gene and uses thereof - Google Patents
Meganuclease variants cleaving a DNA target sequence from the beta-2-microglobulin gene and uses thereof Download PDFInfo
- Publication number
- AU2008218605A1 AU2008218605A1 AU2008218605A AU2008218605A AU2008218605A1 AU 2008218605 A1 AU2008218605 A1 AU 2008218605A1 AU 2008218605 A AU2008218605 A AU 2008218605A AU 2008218605 A AU2008218605 A AU 2008218605A AU 2008218605 A1 AU2008218605 A1 AU 2008218605A1
- Authority
- AU
- Australia
- Prior art keywords
- target
- dna
- sequence
- variant
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010081355 beta 2-Microglobulin Proteins 0.000 title claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 85
- 239000013598 vector Substances 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 241001465754 Metazoa Species 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 17
- 230000009261 transgenic effect Effects 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 129
- 238000003776 cleavage reaction Methods 0.000 description 99
- 230000007017 scission Effects 0.000 description 99
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 85
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 82
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 81
- 239000000178 monomer Substances 0.000 description 70
- 230000035772 mutation Effects 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 57
- 239000002773 nucleotide Substances 0.000 description 52
- 125000003729 nucleotide group Chemical group 0.000 description 52
- 102220527593 Prostaglandin E synthase_R70S_mutation Human genes 0.000 description 48
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 44
- 238000000034 method Methods 0.000 description 44
- 150000007523 nucleic acids Chemical class 0.000 description 44
- 102000039446 nucleic acids Human genes 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 43
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 40
- 108010042407 Endonucleases Proteins 0.000 description 32
- 102000004533 Endonucleases Human genes 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 31
- 238000006467 substitution reaction Methods 0.000 description 30
- 102220556562 Delta and Notch-like epidermal growth factor-related receptor_Y33R_mutation Human genes 0.000 description 28
- 102220591832 Potassium voltage-gated channel subfamily B member 1_D75R_mutation Human genes 0.000 description 23
- 238000012216 screening Methods 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000002744 homologous recombination Methods 0.000 description 15
- 230000006801 homologous recombination Effects 0.000 description 15
- 238000002703 mutagenesis Methods 0.000 description 15
- 231100000350 mutagenesis Toxicity 0.000 description 15
- 230000008439 repair process Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000005782 double-strand break Effects 0.000 description 14
- 239000000833 heterodimer Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102220005406 rs28928875 Human genes 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 102220556561 Delta and Notch-like epidermal growth factor-related receptor_Q44W_mutation Human genes 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 102220369054 c.94A>G Human genes 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 108091081548 Palindromic sequence Proteins 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 230000013011 mating Effects 0.000 description 10
- 102220569779 Pyridoxal-dependent decarboxylase domain-containing protein 1_S40Q_mutation Human genes 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000002708 random mutagenesis Methods 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 101100437218 Homo sapiens B2M gene Proteins 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000006780 non-homologous end joining Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000005030 transcription termination Effects 0.000 description 8
- 102220510130 Coagulation factor VIII_D75Y_mutation Human genes 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 102220476113 Vacuolar protein sorting-associated protein 33A_K28R_mutation Human genes 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 230000007018 DNA scission Effects 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 6
- 102220485790 Destrin_S40R_mutation Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 102220606761 Gap junction beta-1 protein_N30V_mutation Human genes 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 239000013611 chromosomal DNA Substances 0.000 description 6
- 238000010363 gene targeting Methods 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 229910009891 LiAc Inorganic materials 0.000 description 5
- 102220476565 NF-kappa-B inhibitor alpha_S32T_mutation Human genes 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 102220580831 Serine/threonine-protein kinase STK11_K96R_mutation Human genes 0.000 description 5
- 102220560339 Stromal cell-derived factor 1_Y33A_mutation Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 102220005171 rs33914359 Human genes 0.000 description 5
- 102200155456 rs35947557 Human genes 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 102220476563 NF-kappa-B inhibitor alpha_S32A_mutation Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 102220280971 rs1253463092 Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- BUZOGVVQWCXXDP-VPENINKCSA-N 8-oxo-dGTP Chemical compound O=C1NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 BUZOGVVQWCXXDP-VPENINKCSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 101150076800 B2M gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 102220533129 WW domain-containing oxidoreductase_K28T_mutation Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 102220369055 c.96C>G Human genes 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102220160907 rs886062986 Human genes 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 101150029062 15 gene Proteins 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102220548720 Delta and Notch-like epidermal growth factor-related receptor_Q38A_mutation Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102220527083 Procollagen C-endopeptidase enhancer 1_D75S_mutation Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 102220471762 Proteasome subunit alpha type-7_K28A_mutation Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 102220289727 rs1253463092 Human genes 0.000 description 2
- 102200108088 rs1555526742 Human genes 0.000 description 2
- 102220131518 rs201347216 Human genes 0.000 description 2
- 102220056952 rs730880947 Human genes 0.000 description 2
- 102220262471 rs767354237 Human genes 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102220488155 Bone morphogenetic protein receptor type-2_Q92L_mutation Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102220600549 C-C chemokine receptor type 5_S40D_mutation Human genes 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 102220510142 Coagulation factor VIII_D75E_mutation Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102220556550 Delta and Notch-like epidermal growth factor-related receptor_R68A_mutation Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100162704 Emericella nidulans I-AniI gene Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 102220576563 HLA class I histocompatibility antigen, A alpha chain_R68K_mutation Human genes 0.000 description 1
- 102220576068 HLA class I histocompatibility antigen, B alpha chain_Y33D_mutation Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 102220466851 HLA class II histocompatibility antigen, DR beta 4 chain_V59A_mutation Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100467529 Homo sapiens RAG1 gene Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000289419 Metatheria Species 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102220617997 Phenylalanine-4-hydroxylase_R68S_mutation Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102220526774 Protein MTSS 1_D56E_mutation Human genes 0.000 description 1
- 102220537299 Protein NDRG2_N30R_mutation Human genes 0.000 description 1
- 102220620962 Protein pitchfork_P83A_mutation Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 102220577261 Stromal cell-derived factor 1_R68E_mutation Human genes 0.000 description 1
- 102220577259 Stromal cell-derived factor 1_R68Q_mutation Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102220602177 Synaptotagmin-3_F54A_mutation Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 102220585944 Transthyretin_S72P_mutation Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102220362486 c.167A>G Human genes 0.000 description 1
- 102220347825 c.207C>G Human genes 0.000 description 1
- 102220414144 c.275A>G Human genes 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011819 knockout animal model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000016434 protein splicing Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 102220242597 rs1005062028 Human genes 0.000 description 1
- 102220218299 rs1060503484 Human genes 0.000 description 1
- 102220232576 rs1085307646 Human genes 0.000 description 1
- 102220235661 rs1131691837 Human genes 0.000 description 1
- 102220156594 rs116793431 Human genes 0.000 description 1
- 102200080006 rs118204447 Human genes 0.000 description 1
- 102220017736 rs137854215 Human genes 0.000 description 1
- 102220014106 rs142059019 Human genes 0.000 description 1
- 102200144532 rs142951029 Human genes 0.000 description 1
- 102220256808 rs149398412 Human genes 0.000 description 1
- 102220340175 rs1555191568 Human genes 0.000 description 1
- 102220050493 rs193921030 Human genes 0.000 description 1
- 102200029475 rs200313585 Human genes 0.000 description 1
- 102220125357 rs201745474 Human genes 0.000 description 1
- 102220005504 rs281860657 Human genes 0.000 description 1
- 102220005407 rs28928875 Human genes 0.000 description 1
- 102200082929 rs33924146 Human genes 0.000 description 1
- 102220022283 rs397509331 Human genes 0.000 description 1
- 102220093874 rs558707786 Human genes 0.000 description 1
- 102200006402 rs587778189 Human genes 0.000 description 1
- 102220044643 rs587781450 Human genes 0.000 description 1
- 102200025917 rs72547556 Human genes 0.000 description 1
- 102220056650 rs730881057 Human genes 0.000 description 1
- 102220067424 rs757120802 Human genes 0.000 description 1
- 102220261990 rs776085350 Human genes 0.000 description 1
- 102220070981 rs794728706 Human genes 0.000 description 1
- 102220079853 rs797045893 Human genes 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
WO 2008/102274 PCT/IB2008/001334 MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE BETA-2-MICROGLOBULIN GENE AND USES THEREOF The invention relates to a meganuclease variant cleaving a DNA target sequence from the beta-2-microglobulin gene, to a vector encoding said variant, 5 to a cell, an animal or a plant modified by said vector and to the use of said meganuclease variant and derived products for genome therapy ex vivo (gene cell therapy), and genome engineering. Proteins from the Major Histocompatibility Complex (MHC, also called HLA for huhnans) have a major role in allorecognition. These proteins present 10 antigenic peptides to T cells. They can be classified in two different complexes, MHC class I and MHC class II. MHC class I complexes are ligands or specific T cells and NK cells immunoglobulin-like receptors. They involve highly polymorphic proteins and a small polypeptide, the P2-microglobulin, necessary for assembly of MHC I complexes at the cell surface (Zijlstra et al., Nature, 1990, 344, 742-746). Since the 15 other components of the complex are encoded by multigenic families, knocking-out the p2-microglobulin gene (B2M in human) is the simplest way to suppress MHC I complexes (Koller et al., Proc. Nat. Acad. Sci. U. S. A., 1989, 86, 8932-8935 ; Zijlstra et al., Nature, 1990, 344, 742-746). Because of their pivotal role in allorecognition, MHC proteins are 20 also major players in graft rejection. One could hypothesize that disruption of MHC class I proteins would at least partly alleviate graft rejection. However, studies in mice have provided a more mitigated picture. Whereas hematopoietic stem cells from p2m -/- mice are quickly rejected (Bix et al., Nature, 1991, 349, 329-331 ; Liao et al., Science, 1991, 253, 199-202 ; Huang et al., J. Immunol., 2005, 175, 3753-3761; 25 Ruggeri et al., Immunol Rev, 2006, 214, 202-218), apparently as a consequence of NK cells activation, renal and pancreatic islets allograft from such KO animals are better tolerated (Markmann et al., Transplantation, 1992, 54, 1085-1089; Coffnan et al., J. Immunol., 1993, 151, 425-435). Thus, at least for certain tissues, the inactivation of the human B2M gene could provide a solution for one of the most 30 recurrent problems in transplantation. This could be used in many applications in cell therapy, for pancreatic, renal, and muscular tissues, including heart: precursor cells could be cultivated, treated ex vivo, and retransplanted into the patient.
WO 2008/102274 PCT/IB2008/001334 2 In adition, like immunoglobulins, prealbumin, and the beta protein (APP) found in the amyloid of Alzheimer disease, beta-2-microglobulin has a predominantly beta-pleated sheet structure that may adopt the fibrillar conformation of amyloid in certain pathologic states (Cunningham et al., Biochemistry, 1973, 12: 5 4811-4821). This includes Hemodialysis-Related Amyloidosis (HRA; Gorevic et al., 1986, Proc. Nat. Acad. Sci. 83: 7908-7912). Zingraff et al. (New Eng. J. Med., 1990, 323: 1070-1071) described a patient with severe renal insufficiency who had beta-2 microglobulin amyloidosis despite the fact that dialysis had never been performed. The authors suggested also that some B2M variants are more amyloidogenic than 10 others. Thus, the inactivation of the human B2M gene could also provide a solution for treating pathologies associated with a fibrillar conformation of beta-2 microglobulin such as HRA. Furthermore, the beta-2 microglobulin is highly expressed in the majority of cells; insertion of an exogenous gene of interest at the beta-2 15 microglobulin locus has the advantage of reproducible expression levels of the recombinant protein. Thus, gene targeting at the beta-2 microglobulin locus allows the engineering of transgenic animals or recombinant cell lines producing high level of a protein of interest. Homologous gene targeting strategies have been used to knock out 20 endogenous genes (Capecchi, M.R., Science, 1989, 244, 1288-1292) including the mouse B2M (or 02m) gene (Koller et al., Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 8932-8935), or knock-in exogenous sequences in the chromosome. Basically, a DNA sharing homology with the targeted sequence was introduced into the cell's nucleus, and the endogenous homologous recombination machinery provides for the next steps 25 (figure La). Homologous recombination (HR), is a very conserved DNA maintenance pathway involved in the repair of DNA double-strand breaks (DSBs) and other DNA lesions (Rothstein, Methods Enzymol., 1983, 101, 202-211; Paques et al., Microbiol Mol Biol Rev, 1999, 63, 349-404; Sung et al., Nat. Rev. Mol. Cell. Biol., 2006, 7, 739-750) but it also underlies many biological phenomenon, such as the meiotic 30 reassortiment of alleles in meiosis (Roeder, Genes Dev., 1997, 11, 2600-2621), mating type interconversion in yeast (Haber, Annu. Rev. Genet., 1998, 32, 561-599), and the "homing" of class I introns and inteins to novel alleles. HR usually promotes the WO 2008/102274 PCT/IB2008/001334 3 exchange of genetic information between endogenous sequences, but in gene targeting experiments, it is used to promote exchange between an endogenous chromosomal sequence and an exogenous DNA construct. However, the process has a low efficiency (10-6 to 10-9 of transfected cells). 5 This efficiency can be enhanced by a DNA double-strand break (DSB) in the targeted locus. Such DSBs can be created by meganucleases, which are by definition sequence-specific endonucleases recognizing large sequences (Thierry, A. and B. Dujon, Nucleic Acids Res., 1992, 20, 5625-5631). These proteins can cleave unique sites in living cells, thereby enhancing gene targeting by 1000-fold or 10 more in the vicinity of the cleavage site (Puchta et al., Nucleic Acids Res., 1993, 21, 5034-5040 ; Rouet et al., Mol. Cell. Biol., 1994, 14, 8096-8106 ; Choulika et al., Mol. Cell. Biol., 1995, 15, 1968-1973; Puchta et al., Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 5055-5060 ; Sargent et al., Mol. Cell. Biol., 1997, 17, 267-277; Cohen-Tannoudji et al., Mol. Cell. Biol., 1998, 18, 1444-1448 ; Donoho, et al., Mol. Cell. Biol., 1998, 15 18, 4070-4078; Elliott et al., Mol. Cell. Biol., 1998, 18, 93-101), (figure lb). However, although several hundreds of natural meganucleases, also referred to as "homing endonucleases" have been identified (Chevalier, B.S. and B.L. Stoddard, Nucleic Acids Res., 2001, 29, 3757-3774), the repertoire of cleavable sequences is too limited to address the complexity of the genomes, and there is usually no cleavable 20 site in a chosen gene. Theoretically, the making of artificial sequence specific endonucleases with chosen specificities could alleviate this limit. Therefore, the making of meganucleases with tailored specificities is under intense investigation. Recently, fusion of Zinc-Finger Proteins with the catalytic domain of the FokI, a class IIS restriction endonuclease, were used to make functional 25 sequence-specific endonucleases (Smith et al., Nucleic Acids Res., 1999, 27, 674-681; Bibikova et al., Mol. Cell. Biol., 2001, 21, 289-297 ; Bibikova et al., Genetics, 2002, 161, 1169-1175 ; Bibikova et al., Science, 2003, 300, 764; Porteus, M.H. and D. Baltimore, Science, 2003, 300, 763-; Alwin et al., Mol. Ther., 2005, 12, 610-617; Umov et al., Nature, 2005, 435, 646-651; Porteus, M.H., Mol. Ther., 2006, 13, 438 30 446). Such nucleases could recently be used for the engineering of the ILR2G gene in human cells from the lymphoid lineage (Urnov et al., Nature, 2005, 435, 646-65 1).
WO 2008/102274 PCT/IB2008/001334 4 The binding specificity of Cys2-His2 type Zinc-Finger Proteins (ZFP), is easy to manipulate, probably because they represent a simple (specificity driven by essentially four residues per finger), and modular system (Pabo et al., Annu. Rev. Biochem., 2001, 70, 313-340 ; Jamieson et al., Nat. Rev. Drug Discov., 2003, 2, 5 361-368. Studies from the Pabo (Rebar, E.J. and C.O. Pabo, Science, 1994, 263, 671 673 ; Kim, J.S. and C.O. Pabo, Proc. Natl. Acad. Sci. U S A, 1998, 95, 2812-2817), Klug (Choo, Y. and A. Klug, Proc. Natl. Acad. Sci. USA, 1994, 91, 11163-11167 ; Isalan M. and A. Klug, Nat. Biotechnol., 2001, 19, 656-660) and Barbas (Choo, Y. and A. Klug, Proc. Natl. Acad. Sci. USA, 1994, 91, 11163-11167 ; Isalan M. and A. 10 Klug, Nat. Biotechnol., 2001, 19, 656-660) laboratories resulted in a large repertoire of novel artificial ZFPs, able to bind most G/ANNG/ANNG/ANN sequences. Nevertheless, ZFPs might have their limitations, especially for applications requiring a very high level of specificity, such as therapeutic applications. It was recently shown that FokI nuclease activity in fusion acts with either one 15 recognition site or with two sites separated by varied distances via a DNA loop including in the presence of some DNA-binding defective mutants of FokI (Catto et al., Nucleic Acids Res., 2006, 34, 1711-1720). Thus, specificity might be very degenerate, as illustrated by toxicity in mammalian cells and Drosophila (Bibikova et al., Genetics, 2002, 161, 1169-1175 ; Bibikova et al., Science, 2003, 300, 764-.). 20 In the wild, meganucleases are essentially represented by homing endonucleases. Homing Endonucleases (HEs) are a widespread family of natural meganucleases including hundreds of proteins families (Chevalier, B.S. and B.L. Stoddard, Nucleic Acids Res., 2001, 29, 3757-3774). These proteins are encoded by mobile genetic elements which propagate by a process called "homing": the 25 endonuclease cleaves a cognate allele from which the mobile element is absent, thereby stimulating a homologous recombination event that duplicates the mobile DNA into the recipient locus. Given their exceptional cleavage properties in terms of efficacy and specificity, they could represent ideal scaffold to derive novel, highly specific endonucleases. 30 HEs belong to four major families. The LAGLIDADG family, named after a conserved peptidic motif involved in the catalytic center, is the most widespread and the best characterized group. Seven structures are now available.
WO 2008/102274 PCT/IB2008/001334 5 Whereas most proteins from this family are monomeric and display two LAGLIDADG motifs, a few ones have only one motif, but dimerize to cleave palindromic or pseudo-palindromic target sequences. Although the LAGLIDADG peptide is the only conserved region 5 among members of the family, these proteins share a very similar architecture (figure 2). The catalytic core is flanked by two DNA-binding domains with a perfect two-fold symmetry for homodimers such as I-CreI (Chevalier, et al., Nat. Struct. Biol., 2001, 8, 312-316) and I-MsoI (Chevalier et al., J. Mol. Biol., 2003, 329, 253-269) and with a pseudo symmetry fo monomers such as I-Scel (Moure et al., J. Mol. Biol., 2003, 334, 10 685-69, I-DmoI (Silva et al., J. Mol. Biol., 1999, 286, 1123-1136) or I-AniI (Bolduc et al., Genes Dev., 2003, 17, 2875-2888). Both monomers, or both domains (for monomeric proteins) contribute to the catalytic core, organized around divalent cations. Just above the catalytic core, the two LAGLIDADG peptides play also an essential role in the dimerization interface. DNA binding depends on two typical 15 saddle-shaped pocsap folds, sitting on the DNA major groove. Other domains can be found, for example in inteins such as PI-PfuI (Ichiyanagi et al., J. Mol. Biol., 2000, 300, 889-901) and PI-Scel (Moure et al., Nat. Struct. Biol., 2002, 9, 764-770), which protein splicing domain is also involved in DNA binding. The making of functional chimeric meganucleases, by fusing the N 20 terminal I-DmoI domain with an I-Crel monomer (Chevalier et al., Mol. Cell., 2002, 10, 895-905 ; Epinat et al., Nucleic Acids Res, 2003, 31, 2952-62; International PCT Applications WO 03/078619 and WO 2004/031346) have demonstrasted the plasticity of LAGLIDADG proteins. Besides, different groups have have used a rational approach to 25 locally alter the specificity of the I-Crel (Seligman et al., Genetics, 1997, 147, 1653 1664; Sussman et al., J. Mol. Biol., 2004, 342, 31-41; International PCT Applications WO 2006/097784 and WO 2006/097853; Arnould et al., J. Mol. Biol., 2006, 355, 443-458; Rosen et al., Nucleic Acids Res., 2006, 34, 4791-4800 ; Smith et al., Nucleic Acids Res., 2006, 34, e149), I-Scel (Doyon et al., J. Am. Chem. Soc., 2006, 128, 30 2477-2484), PI-Scel (Gimble et al., J. Mol. Biol., 2003, 334, 993-1008 ) and I-MsoI (Ashworth et al., Nature, 2006, 441, 656-659).
WO 2008/102274 PCT/IB2008/001334 6 In addition, hundreds of I-Crel derivatives with locally altered specificity were engineered by combining the semi-rational approach and High Throughput Screening: - Residues Q44, R68 and R70 or Q44, R68, D75 and 177 of I-Crel 5 were mutagenized and a collection of variants with altered specificity in positions ± 3 to 5 of the DNA target (5NNN DNA target) were identified by screening (International PCT Applications WO 2006/097784 and WO 2006/097853; Arnould et al., J. Mol. Biol., 2006, 355, 443-458; Smith et al., Nucleic Acids Res., 2006, 34, e149). 10 - Residues K28, N30 and Q38, N30, Y33 and Q38 or K28, Y33, Q38 and S40 of I-Crel were mutagenized and a collection of variants with altered speci ficity in positions ± 8 to 10 of the DNA target (1 ONNN DNA target) were identified by screening (Smith et al., Nucleic Acids Res., 2006, 34, e149). Residues 28 to 40 and 44 to 77 of I-Crel were shown to form two 15 separable functional subdomains, able to bind distinct parts of a homing endonuclease half-site (Smith et al. Nucleic Acids Res., 2006, 34, e149). The combination of mutations from the two subdomains of I-CreI within the same monomer allowed the design of novel chimeric molecules (homodimers) able to cleave a palindromic combined DNA target sequence 20 comprising the nucleotides in positions ± 3 to 5 and ± 8 to 10 which are bound by each subdomain (Smith et al., Nucleic Acids Res., 2006, 34, e149). Two different variants were combined and assembled in a functional heterodimeric endonuclease able to cleave a chimeric target resulting from the fusion of a different half of each variant DNA target sequence (Arnould et al., precited; 25 International PCT Application WO 2006/097854). Interestingly, the novel proteins had kept proper folding and stability, high activity, and a narrow specificity The combination of the two former steps allows a larger combinatorial approach, involving four different subdomains. The different subdomains can be modified separately and combined to obtain an entirely redesigned 30 meganuclease variant (heterodimer or single-chain molecule) with chosen specificity, as illustrated on figure 3. In a first step, couples of novel meganucleases are combined in new molecules ("half-meganucleases") cleaving palindromic targets derived from WO 2008/102274 PCT/IB2008/001334 7 the target one wants to cleave. Then, the combination of such "half-meganuclease" can result in an heterodimeric species cleaving the target of interest. The assembly of four set of mutations into heterodimeric endonucleases cleaving a model target sequence or a sequence from the human RAG 1 gene has been described in Smith et al. 5 (Nucleic Acids Res., 2006, 34, e149). These variants can be used to cleave genuine chromosomal sequences and have paved the way for novel perspectives in several fields, including gene therapy. The Inventors have identified a series of DNA targets in the beta-2 10 microglobulin gene that could be cleaved by I-Crel variants (figure 4). The combinatorial approach described in figure 3 was used to entirely redesign the DNA binding domain of the I-Crel protein and thereby engineer novel meganucleases with fully engineered specificity, to cleave DNA targets from the human B2M gene. The I Crel variants which are able to cleave a genomic DNA target from the human B2M 15 gene can be used for inactivating the human B2M gene (figure 6) ex vivo, for the purpose of preventing xenograft rejection in human. Other potential applications include genome therapy of pathologies associated with a fibrillar conformation of beta-2 microglobulin and genome engineering at the beta-2 microglobulin locus (knock-out and knock in). 20 The invention relates to an I-Crel variant wherein at least one of the two I-Crel monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, and is able to cleave a DNA target sequence from the beta-2 microglobulin gene. 25 The cleavage activity of the variant according to the invention may be measured by any well-known, in vitro or in vivo cleavage assay, such as those described in the International PCT Application WO 2004/067736; Epinat et al., Nucleic Acids Res., 2003, 31, 2952-2962; Chames et al., Nucleic Acids Res., 2005, 33, e178 and Arnould et al., J. Mol. Biol., 2006, 355, 443-458. For example, the 30 cleavage activity of the variant of the invention may be measured by a direct repeat recombination assay, in yeast or mammalian cells, using a reporter vector. The reporter vector comprises two truncated, non-functional copies of a reporter gene WO 2008/102274 PCT/IB2008/001334 8 (direct repeats) and the genomic DNA target sequence within the intervening sequence, cloned in a yeast or a mammalian expression vector. Expression of the variant results in a functional endonuclease which is able to cleave the genomic DNA target sequence. This cleavage induces homologous recombination between the direct 5 repeats, resulting in a functional reporter gene, whose expression can be monitored by appropriate assay. Definitions - Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or 10 Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue. - Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k 15 represents g or t, s represents g or c, w represents a or t, m represents a or c, y repre sents t or c (pyrimidine nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c. - by "meganuclease", is intended an endonuclease having a double stranded DNA target sequence of 12 to 45 bp. Said meganuclease is either a dimeric 20 enzyme, wherein each domain is on a monomer or a monomeric enzyme comprising the two domains on a single polypeptide. - by "meganuclease domain" is intended the region which interacts with one half of the DNA target of a meganuclease and is able to associate with the other domain of the same meganuclease which interacts with the other half of the 25 DNA target to form a functional meganuclease able to cleave said DNA target. - by "meganuclease variant" or "variant" is intented a meganuclease obtained by replacement of at least one residue in the amino acid sequence of the wild-type meganuclease (natural meganuclease) with a different amino acid. - by "functional variant" is intended a variant which is able to cleave 30 a DNA target sequence, preferably said target is a new target which is not cleaved by the parent meganuclease. For example, such variants have amino acid variation at WO 2008/102274 PCT/IB2008/001334 9 positions contacting the DNA target sequence or interacting directly or indirectly with said DNA target. - by "meganuclease variant with novel specificity" is intended a variant having a pattern of cleaved targets different from that of the parent 5 meganuclease. The terms "novel specificity", "modified specificity", "novel cleavage specificity", "novel substrate specificity" which are equivalent and used indifferently, refer to the specificity of the variant towards the nucleotides of the DNA target sequence. - by "I-Crel" is intended the wild-type I-CreI having the sequence 10 SWISSPROT P05725 or pdb accession code lg9y, corresponding to the sequence SEQ ID NO: 1 or SEQ ID NO: 107 in the sequence listing. - by "domain" or "core domain" is intended the "LAGLIDADG homing endonuclease core domain" which is the characteristic aipip 2 a 2 p3p 4 a 3 fold of the homing endonucleases of the LAGLIDADG family, corresponding to a sequence 15 of about one hundred amino acid residues. Said domain comprises four beta-strands (pip2P3p4) folded in an antiparallel beta-sheet which interacts with one half of the DNA target. This domain is able to associate with another LAGLIDADG homing endonuclease core domain which interacts with the other half of the DNA target to form a functional endonuclease able to cleave said DNA target. For example, in the 20 case of the dimeric homing endonuclease I-CreI (163 amino acids), the LAGLIDADG homing endonuclease core domain corresponds to the residues 6 to 94. - by "single-chain meganuclease" is intended a meganuclease comprising two LAGLIDADG homing endonuclease domains or core domains linked by a peptidic spacer. The single-chain meganuclease is able to cleave a chimeric DNA 25 target sequence comprising one different half of each parent meganuclease target sequence. - by "subdomain" is intended the region of a LAGLIDADG homing endonuclease core domain which interacts with a distinct part of a homing endo nuclease DNA target half-site. 30 - by "beta-hairpin" is intended two consecutive beta-strands of the antiparallel beta-sheet of a LAGLIDADG homing endonuclease core domain ((12 or,p3P4) which are connected by a loop or a turn, WO 2008/102274 PCT/IB2008/001334 10 - by "I-CreI site" is intended a 22 to 24 bp double-stranded DNA sequence which is cleaved by I-CreI. I-CreI sites include the wild-type (natural) non palindromic I-CreI homing site and the derived palindromic sequences such as the sequence 5'- t-1 2 c-Ila-Ioa.
9 a.sa.
7 c- 6 g 5 t.
4 c.
3 g-2tla+ 1 Ic+ 2 g+ 3 a+ 4 c+ 5 g6t+7t+8t.9telog+1ia+ 12 also 5 called C1221 (SEQ ID NO :2; figure 5). - by "DNA target", "DNA target sequence", "target sequence", "target-site", "target" , "site"; "site of interest"; "recognition site", "recognition sequence", "homing recognition site", "homing site", "cleavage site" is intended a 20 to 24 bp double-stranded palindromic, partially palindromic (pseudo-palindromic) or 10 non-palindromic polynucleotide sequence that is recognized and cleaved by a LAGLIDADG homing endonuclease such as I-Crel, or a variant, or a single-chain chimeric meganuclease derived from I-Crel. These terms refer to a distinct DNA location, preferably a genomic location, at which a double stranded break (cleavage) is to be induced by the meganuclease. The DNA target is defined by the 5' to 3' 15 sequence of one strand of the double-stranded polynucleotide, as indicate above for C1221. Cleavage of the DNA target occurs at the nucleotides in positions +2 and -2, respectively for the sense and the antisense strand. Unless otherwiwe indicated, the position at which cleavage of the DNA target by an I-Cre I meganuclease variant occurs, corresponds to the cleavage site on the sense strand of the DNA target. 20 - by "DNA target half-site", "half cleavage site" or half-site" is intended the portion of the DNA target which is bound by each LAGLIDADG homing endonuclease core domain. - by "chimeric DNA target" or "hybrid DNA target" is intended the fusion of a different half of two parent meganuclease target sequences. In addition at 25 least one half of said target may comprise the combination of nucleotides which are bound by at least two separate subdomains (combined DNA target). - by "beta-2-microglobulin gene" is intended the beta-2 microglobulin gene of a mammal. For example, the human beta-2-microglobulin gene (B2M, 6673bp) is situated from positions 42790977 to 42797649 of the sequence 30 corresponding to accession number NC_000015. The B2M gene comprises four exons (Exon 1: positions 1-127; Exon 2: positions 3937 to 4215; Exon 3: 4843 to 4870; Exon 4: positions 6121 to 6673). The ORF which is from position 61 (Exon 1) to WO 2008/102274 PCT/IB2008/001334 11 positions 4856 (Exon 3), is flanked by a short and a long untranslated region, respectively at its 5' and 3' ends (Figure 4). - by "DNA target sequence from the beta-2-microglobulin gene", "genomic DNA target sequence", " genomic DNA cleavage site", "genomic DNA 5 target" or "genomic target" is intended a 20 to 24 bp sequence of the beta-2 microglobulin gene of a mammal which is recognized and cleaved by a meganuclease variant. - by "vector" is intended a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. 10 - by "homologous" is intended a sequence with enough identity to another one to lead to a homologous recombination between sequences, more particularly having at least 95 % identity, preferably 97 % identity and more prefera bly 99 %. - "identity" refers to sequence identity between two nucleic acid 15 molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions 20 shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings. - "individual" includes mammals, as well as other vertebrates (e.g., 25 birds, fish and reptiles). The terms "mammal" and "mammalian", as used herein, refer to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include humans and other primates (e.g., monkeys, chimpanzees), rodents 30 (e.g., rats, mice, guinea pigs) and others such as for example: cows, pigs and horses. - by mutation is intended the substitution, deletion, insertion of one or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide WO 2008/102274 PCT/IB2008/001334 12 sequence. Said mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA. The variant according to the invention may be an homodimer or an 5 heterodimer. Preferably, it is an heterodimer wherein both monomers are mutated in positions 26 to 40 and/or 44 to 77. More preferably, both monomers have different substitutions both in positions 26 to 40 and 44 to 77 of I-CreI. In a preferred embodiment of said variant, said substitution(s) in the subdomain situated from positions 44 to 77 of I-CreI are in positions 44, 68, 70, 75 10 and/or 77. In another preferred embodiment of said variant, said substitution(s) in the subdomain situated from positions 26 to 40 of I-CreI are in positions 26, 28, 30, 32, 33, 38 and/or 40. In another preferred embodiment of said variant, it comprises one or 15 more mutations at positions of other amino acid residues which contact the DNA target sequence or interact with the DNA backbone or with the nucleotide bases, directly or via a water molecule; these residues are well-known in the art (Jurica et al., Molecular Cell., 1998, 2, 469-476; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269). In particular, additional substitutions may be introduced at positions contacting the 20 phosphate backbone, for example in the final C-terminal loop (positions 137 to 143). Preferably said residues are involved in binding and cleavage of said DNA cleavage site. More preferably, said residues are in positions 138, 139, 142 or 143 of I-CreI. Two residues may be mutated in one variant provided that each mutation is in a different pair of residues chosen from the pair of residues in positions 138 and 139 25 and the pair of residues in positions 142 and 143. The mutations which are introduced modify the interaction(s) of said amino acid(s) of the final C-terminal loop with the phosphate backbone of the I-CreI site. Preferably, the residue in position 138 or 139 is substituted by an hydrophobic amino acid to avoid the formation of hydrogen bonds with the phosphate backbone of the DNA cleavage site. For example, the residue in 30 position 138 is substituted by an alanine or the residue in position 139 is substituted by a methionine. The residue in position 142 or 143 is advantageously substituted by a small amino acid, for example a glycine, to decrease the size of the side chains of WO 2008/102274 PCT/IB2008/001334 13 these amino acid residues. More, preferably, said substitution in the final C-terminal loop modify the specificity of the variant towards the nucleotide in positions ± 1 to 2, 6 to 7 and/or ± 11 to 12 of the I-Crel site. In another preferred embodiment of said variant, it comprises one or 5 more additional mutations that improve the binding and/or the cleavage properties of the variant towards the DNA target sequence from the beta-2 microglobulin gene. The additional residues which are mutated may be on the entire I CreI sequence, and in particular in the C-terminal half of I-Crel (positions 80 to 163). For example, the variant comprises one or more additional substitutions in positions: 10 2, 4, 19, 24, 31, 43, 49, 50, 53, 54, 56, 57, 59, 60, 64, 66, 69, 72, 73, 80, 81, 82, 83, 85, 87, 89, 92, 94, 96, 100, 103, 105, 107, 110, 111, 117, 120, 128, 129, 132, 135, 140, 142, 147, 153, 154, 155, 156, 157, 158, 159, 161, 163. Preferably said substitutions are selected from the group consisting of: N21, N2Y, K4Q, G19S, 124F, 124V, Q31L, F43L, T49A, Q50R, W53R, F54L, D56E, D56G, K57N, V59A, D60E, 15 D60G, D60N, V64A, V64D, Y66C, D69G, D69E, S72F, S72P, S72T, V731, E80G, 181T, I81V, K82E, K82R, P83Q, P83A, H85R, F87L, T89A, T891, Q92L, Q92R, F94L, F94Y, K96R, K100R, KOOQ, N103T, N103S, V105A, K107R, E11OD, E11OG, QlllL, E117G, D120G, W128R, V129A, 1132V, L135P, T140M, K142R, T147A, T147N, D153G, D153V, S154G, L155Q, S156N, S156R, E157V, K158N, 20 K159Q, K159R, Sl61P, S161F, S162F, P163L and P163Q. More preferably, said mutations are selected from the group consisting of: G19S, 124V, F54L, F87L and 1132V. The variant may also comprise one or two additional residues inserted at the C-terminus of the I-CreI sequence (positions 164 and 165); for example 25 a G can be inserted at position 164, a T or a P at position 165 In another preferred embodiment of said variant, said substitutions are replacement of the initial amino acids with amino acids selected from the group consisting of: A, D, E, G, H, K, N, P, Q, R, S, T, Y, C, V, L and W. The variant of the invention may be derived from the wild-type I 30 CreI (SEQ ID NO: 1) or an I-Crel scaffold protein, such as the scaffold of SEQ ID NO: 106 (167 amino acids) having the insertion of an alanine in position 2, the WO 2008/102274 PCT/IB2008/001334 14 substitution D75N, and the insertion of AAD at the C-terminus (positions 164 to 166) of the I-Crel sequence. In addition, the variants of the invention may include one or more residues inserted at the NH 2 terminus and/or COOH terminus of the sequence. For 5 example, a tag (epitope or polyhistidine sequence) is introduced at the NH 2 terminus and/or COOH terminus; said tag is useful for the detection and/or the purification of said variant. The variant according to the present invention may be an homodimer which is able to cleave a palindromic or pseudo-palindromic DNA target 10 sequence. Alternatively, said variant is an heterodimer, resulting from the association of a first and a second monomer having different substitutions in positions 26 to 40 and 44 to 77 of I-Crel, said heterodimer being able to cleave a non palindromic DNA target sequence from the beta-2-microglobulin gene. 15 The DNA target sequence which is cleaved by said variant may be in an exon or in an intron of the beta-2-microglobulin gene. In another preferred embodiment of said variant, said DNA target sequence is from the human beta-2-microglobulin gene (B2M gene). Preferably said DNA target sequence is selected from the group consisting of the sequences SEQ ID 20 NO: 82 to 91 (24 bp; Figures 4 and 15) and the 20 to 22 bp derived sequences lacking one or two of the terminal base pairs from one or both ends of said 24 bp sequence. Since coding exons represent only a small fraction of the gene (Figure 4), most potential target sites are found in intronic sequences or untranslated exonic sequences. However, targets such as B2M18 and B2M20 (SEQ ID NO: 89 and 90) are found in 25 the B2M open reading frame. More preferably, the monomers of the variant have at least the following substitutions, respectively for the first and the second monomer: - Y33R, Q38A, Q44D, R68A, R70S, D75K and 177R (first monomer), and K28R, Y33A, Q38Y, S40Q, Q44A, R68Y, R70S, D75Y and 177K 30 (second monomer); this variant cleaves the B2M4 target which is located in the first intron (figures 4 and 15), WO 2008/102274 PCT/IB2008/001334 15 - S32T, Y33T, Q44T, R68Y, R70S, D75Y and 177V (first monomer), and Y33R, Q38A, Q44N, R68Q, R70S, D75S and 177V (second monomer); this variant cleaves the B2M 10 target which is located in the first intron (figures 4 and 15), -S32G, Y33H, Q44A, R68Y, R70S, D75Y and 177K or S32A, Y33H, 5 Q44A, R68Y, R70S, D75Y and 177K (first monomer) and N30Q, Y33G, Q38C, R68N, R70S, D75N and 177R (second monomer); this variants cleave the B2M1 1 target which is located in the first intron (figures 4 and 15), - S32G, Y33H, Q44A, R68Y, R70S, D75Y and 177K (first monomer), and S32T, Q38S, Q44K, R70S and 177A (second monomer); this variant 10 cleaves the B2M 13 target which is located in the first intron (figures 4 and 15), - S32T, Y33T, Q44K, R68E, R70S and 177R (first monomer), and N30A, Y33T, Q44N, R68K, R70S, D75H and 177F (second monomer); this variant cleaves the B2M14 target which is located in the first intron (figures 4 and 15), - S32R, Y33D, Q44A, R70S, D75E and 177R (first monomer), and 15 N30D, Y33R, Q44K, R68Y, R70S, D75N and 177Q (second monomer); this variant cleaves the B2M 16 target which is located in the first intron (figures 4 and 15), - S32T, Q38W, Q44A, R70S, D75R and 177Y (first monomer), and Y33H, S40Q, Q44N, R70S, D75R and 177Y (second monomer); this variant cleaves the B2M 17 target which is located in the first intron (figures 4 and 15), 20 - Y33H, Q38G, Q44N, R68Y, R70S, D75R and 177V (first monomer), and a second monomer selected from the group consisiting of: N30A, Y33T, Q44N, R68Y, R70S, D75R and 177V; N30H, Y33C, R68Y, R70S, D75R and 177Q; S32G, Y33C, R68Y, R70S, D75R and 177Q; S32R, Y33T, R68Y, R70S, D75R and 177Q; S32G, Y33C, Q44N, R68Y, R70S, D75R and 177Q; S32A, Y33C, Q44N, 25 R68Y, R70S, D75R and 177Q; S32G, Y33S, Q44N, R68Y, R70S, D75R and 177Q; N30H, Y33C, Q44N, R68Y, R70S, D75R and 177V; S32G, Y33C, Q44N, R68Y, R70S, D75R and 177V; Y33C, S40Q, Q44N, R68Y, R70S, D75R and 177V; S32G, Y33S, Q44N, R68Y, R70S, D75R and 177V; S32G, Y33C, Q44T, R68Y, R70S, D75R and 177Q; S32A, Y33C, Q44T, R68Y, R70S, D75R and 177Q ; S32G, Y33C, 30 R68Y, R70S, D75R and 177V; S32G, Y33C, R68Y, R70S and D75R; S32G, Y33C, Q44N, R68Y, R70S, D75R and 177Y; S32A, Y33C, Q44N, R68Y, R70S, D75R and 177Y; S32R, Y33T, R68Y, R70S, D75R, 177Q and D153G; N30H, Y33C, Q44R, WO 2008/102274 PCT/IB2008/001334 16 R68Y, R70S, D75R and 177Q; these variants cleave the B2M18 target which is located in exon 2 (figures 4 and 15, Table VII), - Y33T, S40N, Q44T, R68Y, R70S, D75R and 177V (first monomer), and a second monomer selected from the group consisiting of: K28R, Y33A, Q38Y, 5 S40Q, Q44A, R68S, R70S, D75S and 177R; K28A, Y33S, S40R, R70S and D75N; K28A, Y33T, S40R, R70S and D75N; K28R, Y33A, Q38Y, S40Q, R70S and D75N; K28R, Y33N, Q38R, S40Q, R70S and D75N; K28R, Y33R, Q38Y, S40Q, R70S and D75N; K28R, Y33S, Q38R, S40Q, R70S and D75N; K28R, Y33S, Q38Y, S40Q, R70S and D75N; K28T, Y33T, S40D, R70S and D75; K28T, Y33T, S40R, R70S and 10 D75N; S32G, Y33C and D75N; Y33C and D75N; Y33S, S40R and D75N; Y33S and S40R; N30A and Y33G; N30A and Y33T; N30C and Y33A; N30G and Y33C; N30S, Y33S and Q38T; N30A and S32W; N30H and Y33K; N30R and Y33P; N30K and Y33T; N30P and Y33W; S32G and Y33P; S32T and Y33A; Y33T and S40E; these variants cleave the B2M20 target which is located at the intron 2- exon 3 15 junction (figures 4 and 15; Table VIII), and - K28T, Y33R, S40R, Q44T, R70S and D75Y (first monomer), and N30D, Y33R, Q44N, R68Y, R70S, D75Y and 177Q (second monomer); this variant cleaves the B2M33 target which is located in exon 4 (figures 4 and 15). More preferably, said variant consist of a first monomer having any 20 of the sequences SEQ ID NO: 24 to 28, 126 to 134 and a second monomer having any of the sequences SEQ ID NO: 37 to 77 and 135; this variant which derives from the monomers cleaving the B2M 11 target, as defined above, has additional substitutions that increase the cleavage of the B2M1 1 target (figures 4 and 15; Table IV, V and VI). The heterodimeric variant is advantageously an obligate heterodimer 25 variant having at least one pair of mutations interesting corresponding residues of the first and the second monomers which make an intermolecular interaction between the two I-CreI monomers, wherein the first mutation of said pair(s) is in the first monomer and the second mutation of said pair(s) is in the second monomer and said pair(s) of mutations impairs the formation of functional homodimers from each 30 monomer without preventing the formation of a functional heterodimer, able to cleave the genomic DNA target from the beta-2 microglobulin gene.
WO 2008/102274 PCT/IB2008/001334 17 The monomers have advantageously at least one of the following pairs of mutations, respectively for the first and the second monomer: a) the substitution of the glutamic acid in position 8 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the lysine in 5 position 7 with an acidic amino acid, preferably a glutamic acid (second monomer); the first monomer may further comprise the substitution of at least one of the lysine residues in positions 7 and 96, by an arginine. b) the substitution of the glutamic acid in position 61 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the lysine in 10 position 96 with an acidic amino acid, preferably a glutamic acid (second monomer); the first monomer may further comprise the substitution of at least one of the lysine residues in positions 7 and 96, by an arginine c) the substitution of the leucine in position 97 with an aromatic amino acid, preferably a phenylalanine (first monomer) and the substitution of the 15 phenylalanine in position 54 with a small amino acid, preferably a glycine (second monomer) ; the first monomer may further comprise the substitution of the phenylalanine in position 54 by a tryptophane and the second monomer may further comprise the substitution of the leucine in position 58 or lysine in position 57, by a methionine, and 20 d) the substitution of the aspartic acid in position 137 with a basic amino acid, preferably an arginine (first monomer) and the substitution of the arginine in position 51 with an acidic amino acid, preferably a glutamic acid (second monomer). For example, the first monomer may have the mutation D137R and 25 the second monomer, the mutation R51D. The obligate heterodimer meganuclease comprises advantageously, at least two pairs of mutations as defined in a), b) c) or d), above; one of the pairs of mutation is advantageously as defined in c) or d). Preferably, one monomer comprises the substitution of the lysine residues at positions 7 and 96 by an acidic amino acid 30 and the other monomer comprises the substitution of the glutamic acid residues at positions 8 and 61 by a basic amino acid. More preferably, the obligate heterodimer meganuclease, comprises three pairs of mutations as defined in a), b) and c), above.
WO 2008/102274 PCT/IB2008/001334 18 The obligate heterodimer meganuclease consists advantageously of a first monomer (A) having at least the mutations selected from: (i) E8R, E8K or E8H, E61 R, E6 1K or E61 H and L97F, L97W or L97Y; (ii) K7R, E8R, E61 R, K96R and L97F, or (iii) K7R, E8R, F54W, E61R, K96R and L97F and a second monomer (B) having at least the 5 mutations (iv) K7E or K7D, F54G or F54A and K96D or K96E; (v) K7E, F54G, L58M and K96E, or (vi) K7E, F54G, K57M and K96E. For example, the first monomer may have the mutations K7R, E8R, E61R, K96R and L97F or K7R, E8R, F54W, E61R, K96R and L97F and the second monomer, the mutations K7E, F54G, L58M and K96E or K7E, F54G, K57M and K96E. 10 The subject-matter of the present invention is also a single-chain chimeric meganuclease (fusion protein) derived from an I-Crel variant as defined above. The single-chain meganuclease may comprise two I-Crel monomers, two I CreI core domains (positions 6 to 94 of I-Crel) or a combination of both. Preferably, the two monomers /core domains or the combination of both, are connected by a 15 peptidic linker. The subject-matter of the present invention is also a polynucleotide fragment encoding a variant or a single-chain chimeric meganuclease as defined above; said polynucleotide may encode one monomer of an homodimeric or heterodimeric variant, or two domains/monomers of a single-chain chimeric 20 meganuclease. The subject-matter of the present invention is also a recombinant vector for the expression of a variant or a single-chain meganuclease according to the invention. The recombinant vector comprises at least one polynucleotide fragment encoding a variant or a single-chain meganuclease, as defined above. In a preferred 25 embodiment, said vector comprises two different polynucleotide fragments, each encoding one of the monomers of an heterodimeric variant. A vector which can be used in the present invention includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi 30 synthetic or synthetic nucleic acids. Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are WO 2008/102274 PCT/IB2008/001334 19 linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available. Viral vectors include retrovirus, adenovirus, parvovirus (e. g. adeno associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus 5 (e. g., influenza virus), rhabdovirus (e. g., rabies and vesicular stomatitis virus), para myxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picor navirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e. g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomega lovirus), and poxvirus (e. g., vaccinia, fowlpox and canarypox). Other viruses include 10 Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven 15 Publishers, Philadelphia, 1996). Preferred vectors include lentiviral vectors, and particularly self inactivacting lentiviral vectors. Vectors can comprise selectable markers, for example: neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin 20 phosphotransferase, herpes simplex virus thymidine kinase, adenosine deaminase, glutamine synthetase, and hypoxanthine-guanine phosphoribosyl transferase for eukaryotic cell culture; TRP1 for S. cerevisiae; tetracycline, rifampicin or ampicillin resistance in E. coli. Preferably said vectors are expression vectors, wherein the 25 sequence(s) encoding the variant/single-chain meganuclease of the invention is placed under control of appropriate transcriptional and translational control elements to permit production or synthesis of said variant. Therefore, said polynucleotide is comprised in an expression cassette. More particularly, the vector comprises a repli cation origin, a promoter operatively linked to said encoding polynucleotide, a 30 ribosome-binding site, an RNA-splicing site (when genomic DNA is used), a polyadenylation site and a transcription termination site. It also can comprise an enhancer. Selection of the promoter will depend upon the cell in which the poly- WO 2008/102274 PCT/IB2008/001334 20 peptide is expressed. Preferably, when said variant is an heterodimer, the two poly nucleotides encoding each of the monomers are included in one vector which is able to drive the expression of both polynucleotides, simultaneously. Suitable promoters include tissue specific and/or inducible promoters. Examples of inducible promoters 5 are: eukaryotic metallothionine promoter which is induced by increased levels of heavy metals, prokaryotic lacZ promoter which is induced in response to isopropyl- 0 D-thiogalacto-pyranoside (IPTG) and eukaryotic heat shock promoter which is induced by increased temperature. Examples of tissue specific promoters are skeletal muscle creatine kinase, prostate-specific antigen (PSA), c-antitrypsin protease, human 10 surfactant (SP) A and B proteins, O-casein and acidic whey protein genes. According to another advantageous embodiment of said vector, it includes a targeting construct comprising sequences sharing homologies with the region surrounding the genomic DNA cleavage site as defined above. Alternatively, the vector coding for an I-CreI variant/single-chain 15 meganuclease and the vector comprising the targeting construct are different vectors. More preferably, the targeting DNA construct comprises: a) sequences sharing homologies with the region surrounding the genomic DNA cleavage site as defined above, and b) a sequence to be introduced flanked by sequences as in a). 20 For genome therapy or the making of knock-out animals/cells, the sequence to be introduced is a sequence which inactivates the beta-2 microglobulin gene. Both homologous chromosomes have to be targeted in order to totally inactivate the function of the gene. In addition, said sequence may also delete the b2 microglobulin gene or part thereof, and eventually introduce an exogenous gene or 25 part thereof (knock-in/gene replacement). For making knock-in animals/cells the DNA which repairs the site of interest comprises the sequence of an exogenous gene of interest, and eventually a selection marker, such as the HPRT gene. Alternatively, the sequence to be introduced can be any other sequence used to alter the chromosomal DNA in some specific way including a sequence used to modify a specific sequence, 30 to attenuate or activate the endogenous gene of interest or to introduce a mutation into a site of interest. Such chromosomal DNA alterations may be used for genome engi neering (animal models and recombinant cell lines including human cell lines).
WO 2008/102274 PCT/IB2008/001334 21 Inactivation of the beta-2 microglobulin gene may occur by insertion of a transcription termination signal that will interrupt the transcription, and result in a truncated protein (Figure 6a). In this case, the sequence to be introduced comprises, in the 5' to 3' orientation: at least a transcription termination sequence (polyAl), 5 preferably said sequence further comprises a marker cassette including a promoter and the marker open reading frame (ORF) and a second transcription termination sequence (polyA2; figure 6a). This strategy can be used with any meganuclease cleaving a target downstream of the B2M promoter and upsteam of the B2M stop codon, such as any of the targets B2M4, B2M10, B2M 11, B2M13, B2M14, B2M16, B2M17, B2M18 10 and B2M20 (SEQ ID NO: 82 to 90; figures 4 and 15). Inactivation of the beta-2 microglobulin gene may also occur by insertion of a marker gene within the B2M open reading frame (ORF), that would disrupt the coding sequence (figure 6b). The insertion can in addition be associated with deletions of ORF sequences flanking the cleavage site and eventually, the 15 insertion of an exogeneous gene of interest (gene replacement). This strategy can be used with a meganuclease cleaving an exonic sequence, such as for example, a meganuclease cleaving B2M18 or B2M20 (SEQ ID NO: 90, 91). In addition, inactivation of the beta-2 microglobulin gene may also occur by insertion of a sequence that would destabilize the transcript. This strategy 20 can be used with any meganuclease cleaving a target downstream of the B2M promoter such as any of the targets (SEQ ID NO: 82 to 91) presented in figures 4 and 15. Preferably, homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used. Indeed, shared DNA 25 homologies are located in regions flanking upstream and downstream the site of the break and the DNA sequence to be introduced should be located between the two arms. Therefore, the targeting construct is preferably from 200 pb to 6000 pb, more preferably from 1000 pb to 2000 pb; it comprises: a beta-2 microglobulin 30 gene fragment which has at least 200 bp of homologous sequence flanking the target site for repairing the cleavage, and the sequence for inactivating the beta-2 WO 2008/102274 PCT/IB2008/001334 22 microglobulin gene and eventually the sequence of an exogeneous gene of interest for replacing the beta-2 microglobulin gene, as defined above. For the insertion of a sequence, DNA homologies are generally located in regions directly upstream and downstream to the site of the break 5 (sequences immediately adjacent to the break; minimal repair matrix). However, when the insertion is associated with a deletion of ORF sequences flanking the cleavage site, shared DNA homologies are located in regions upstream and downstream the region of the deletion. For example, the B2M target which is cleaved by each of the variant 10 as defined above and the minimal matrix for repairing the cleavage with each variant are indicated in figure 15. The subject-matter of the present invention is also a composition characterized in that it comprises at least one meganuclease as defined above (variant or single-chain derived chimeric meganuclease) and/or at least one expression vector 15 encoding said meganuclease, as defined above. In a preferred embodiment of said composition, it comprises a targeting DNA construct comprising a sequence which inactivates the beta-2 microglobulin gene, flanked by sequences sharing homologies with the genomic DNA cleavage site of said variant, as defined above. 20 Preferably, said targeting DNA construct is either included in a recombinant vector or it is included in an expression vector comprising the polynucleotide(s) encoding the meganuclease according to the invention. The subject-matter of the present invention is also the use of at least one meganuclease and/or one expression vector, as defined above, for the preparation 25 of a medicament for preventing, improving or curing xenograft rejection during transplantation of cells from a donor into an individual (recipient) in need thereof. The subject-matter of the present invention is also the use of at least one meganuclease and/or one expression vector, as defined above, for the preparation of a medicament for preventing, improving or curing a pathological condition 30 associated with a fibrillar conformation of beta-2 microglobulin in an individual in need thereof.
WO 2008/102274 PCT/IB2008/001334 23 The use of the meganuclease may comprise at least the step of (a) inducing in somatic tissue(s) of the donor/ individual a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising at least one recognition and cleavage site of said meganuclease by contacting said cleavage site with said 5 meganuclease, and (b) introducing into said somatic tissue(s) a targeting DNA, wherein said targeting DNA comprises (1) DNA sharing homologies to the region surrounding the cleavage site and (2) DNA which inactivates the beta-2 microglobulin gene upon recombination between the targeting DNA and the chromosomal DNA, as defined above. The targeting DNA is introduced into the somatic tissues(s) under 10 conditions appropriate for introduction of the targeting DNA into the site of interest. The targeting construct may comprise sequences for deleting the beta-2 microglobulin gene and eventually the sequence of an exogenous gene of interest (gene replacement). Alternatively, the beta-2 microglobulin gene may be inactivated by 15 the mutagenesis of the open reading frame, by repair of the double-strands break by non-homologous end joining (Figure 6c). In the absence of a repair matrix, the DNA double-strand break in an exon will be repaired essentially by the error-prone Non Homologous End Joining pathway NHEJ, resulting in small deletions (a few nucleotides), that will inactivate the cleavage site, and result in frameshift mutation. 20 In this case the use of the meganuclease comprises at least the step of : inducing in somatic tissue(s) of the donor/individual a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising at least one recognition and cleavage site of said meganuclease by contacting said cleavage site with said meganuclease, and thereby induce mutagenesis of the beta-2 microglobulin gene open 25 reading frame by repair of the double-strands break by non-homologous end joining. According to the present invention, said double-stranded cleavage may be induced, ex vivo by introduction of said meganuclease into somatic cells (pancreas, kidney, heart, muscle) from the donor/individual and then transplantation of the modified cells into the recipient (xenotransplantation) or back into the diseased 30 individual (pathology associated with a fibrillar conformation of beta-2 microglobulin) .
WO 2008/102274 PCT/IB2008/001334 24 The subject-matter of the present invention is also a method for preventing, improving or curing xenograft rejection during transplantation, in an individual in need thereof, said method comprising at least the step of administering to said individual a composition as defined above, by any means. 5 The subject-matter of the present invention is also a method for preventing, improving or curing a pathological condition associated with a fibrillar conformation of beta-2 microglobulin, in an individual in need thereof, said method comprising at least the step of administering to said individual a composition as defined above, by any means. 10 The subject-matter of the present invention is further the use of a meganuclease as defined above, one or two polynucleotide(s), preferably included in expression vector(s), for genome engineering at the beta-2 microglobulin gene locus (animal models and recombinant cells generation: knock-in or knock-out), for non therapeutic purposes. 15 According to an advantageous embodiment of said use, it is for inducing a double-strand break in a site of interest of the beta-2 microglobulin gene comprising a genomic DNA target sequence, thereby inducing a DNA recombination event, a DNA loss or cell death. According to the invention, said double-strand break is for: repairing 20 a specific sequence in the beta-2 microglobulin gene, modifying a specific sequence in the beta-2 microglobulin gene, restoring a functional beta-2 microglobulin gene in place of a mutated one, attenuating or activating the endogenous beta-2 microglobulin gene, introducing a mutation into a site of interest of the beta-2 microglobulin gene, introducing an exogenous gene or a part thereof, inactivating or deleting the 25 endogenous beta-2 microglobulin gene or a part thereof, translocating a chromosomal arm, or leaving the DNA unrepaired and degraded. According to another advantageous embodiment of said use, said variant, polynucleotide(s), vector, are associated with a targeting DNA construct as defined above. 30 In a first embodiment of the use of the meganuclease according to the present invention, it comprises at least the following steps: 1) introducing a double-strand break at a site of interest of the beta-2 microglobulin gene comprising at WO 2008/102274 PCT/IB2008/001334 25 least one recognition and cleavage site of said meganuclease, by contacting said cleavage site with said meganuclease ; 2) providing a targeting DNA construct comprising the sequence to be introduced flanked by sequences sharing homologies to the targeted locus. Said meganuclease can be provided directly to the cell or through 5 an expression vector comprising the polynucleotide sequence encoding said meganuclease and suitable for its expression in the used cell. This strategy is used to introduce a DNA sequence at the target site, for example to generate knock-in or knock-out animal models or cell lines that can be used for drug testing. In a second embodiment of the use of the meganuclease according to 10 the present invention, it comprises at least the following steps: 1) introducing a double-strand break at a site of interest of the beta-2 microglobulin gene comprising at least one recognition and cleavage site of said meganuclease, by contacting said cleavage site with said meganuclease ; 2) maintaining said broken genomic locus under conditions appropriate for homologous recombination with chromosomal DNA 15 sharing homologies to regions surrounding the cleavage site. In a third embodiment of the use of the meganuclease according to the present invention, it comprises at least the following steps: 1) introducing a double-strand break at a site of interest of the beta-2 microglobulin gene comprising at least one recognition and cleavage site of said meganuclease, by contacting said 20 cleavage site with said meganuclease ; 2) maintaining said broken genomic locus under conditions appropriate for repair of the double-strands break by non homologous end joining. The subject-matter of the present invention is also a method for making a beta-2 microglobulin knock-in or knock-out animal, comprising at least the 25 step of: (a) introducing into a pluripotent precursor cell or an embryo of an animal, a meganuclease, as defined above, so as to into induce a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising a DNA recognition and cleavage site of said meganuclease; simultaneously or consecutively, 30 (b) introducing into the animal precursor cell or embryo of step (a) a targeting DNA, wherein said targeting DNA comprises (1) DNA sharing homologies to the region surrounding the cleavage site and (2) DNA which repairs the site of WO 2008/102274 PCT/IB2008/001334 26 interest upon recombination between the targeting DNA and the chromosomal DNA, so as to generate a genomically modified animal precursor cell or embryo having repaired the site of interest by homologous recombination, (c) developping the genomically modified animal precursor cell or 5 embryo of step (b) into a chimeric animal, and (d) deriving a transgenic animal from the chimeric animal of step (c). Preferably, step (c) comprises the introduction of the genomically modified precursor cell generated in step (b) into blastocysts so as to generate 10 chimeric animals. The subject-matter of the present invention is also a method for making a beta-2 microglobulin knock-in or knock-out cell, comprising at least the step of: (a) introducing into a cell, a meganuclease, as defined above, so as 15 to into induce a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising a DNA recognition and cleavage site for said meganuclease, simultaneously or consecutively, (b) introducing into the cell of step (a), a targeting DNA, wherein said targeting DNA comprises (1) DNA sharing homologies to the region surrounding 20 the cleavage site and (2) DNA which repairs the site of interest upon recombination between the targeting DNA and the chromosomal DNA, so as to generate a recombinant cell having repaired the site of interest by homologous recombination, (c) isolating the recombinant cell of step (b), by any appropriate mean. 25 The targeting DNA is introduced into the cell under conditions appropriate for introduction of the targeting DNA into the site of interest. In a preferred embodiment, said targeting DNA construct is inserted in a vector. Alternatively, the beta-2 microglobulin gene may be inactivated by 30 repair of the double-strands break by non-homologous end joining (Figure 6c). The subject-matter of the present invention is also a method for making a beta-2 microglobulin knock-out animal, comprising at least the step of: WO 2008/102274 PCT/IB2008/001334 27 (a) introducing into a pluripotent precursor cell or an embryo of an animal, a meganuclease, as defined above, so as to induce a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising a DNA recognition and cleavage site of said meganuclease, and thereby generate genomically modified 5 precursor cell or embryo having repaired the double-strands break by non-homologous end joining, (b) developping the genomically modified animal precursor cell or embryo of step (a) into a chimeric animal, and (c) deriving a transgenic animal from a chimeric animal of step (b). 10 Preferably, step (b) comprises the introduction of the genomically modified precursor cell obtained in step (a), into blastocysts, so as to generate chimeric animals. The subject-matter of the present invention is also a method for making a beta-2 microglobulin-deficient cell, comprising at least the step of: 15 (a) introducing into a cell, a meganuclease, as defined above, so as to induce a double stranded cleavage at a site of interest of the beta-2 microglobulin gene comprising a DNA recognition and cleavage site of said meganuclease, and thereby generate genomically modified HPRT deficient cell having repaired the double-strands break, by non-homologous end joining, and 20 (b) isolating the genomically modified HPRT deficient cell of step(a), by any appropriate mean. The cell which is modified may be any cell of interest. For making transgenic/knock-out animals, the cells are pluripotent precursor cells such as embryo derived stem (ES) cells, which are well-kown in the art. For making recombinant cell 25 lines, the cells may advantageously be human cells, for example PerC6 (Fallaux et al., Hum. Gene Ther. 9, 1909-1917, 1998) or HEK293 (ATCC # CRL-1573) cells. Said meganuclease can be provided directly to the cell or through an expression vector comprising the polynucleotide sequence encoding said meganuclease and suitable for its expression in the used cell. 30 For making transgenic animals/recombinant cell lines, including human cell lines expressing an heterologous protein of interest, the targeting DNA comprises the sequence of the exogenous gene encoding the protein of interest, and WO 2008/102274 PCT/IB2008/001334 28 eventually a marker gene, flanked by sequences upstream and downsteam the beta-2 microglobulin gene, as defined above, so as to generate genomically modified cells (animal precursor cell or embryo/animal or human cell) having replaced the beta-2 microglobulin gene by the exogenous gene of interest, by homologous recombination. 5 The exogenous gene and the marker gene are inserted in an appropriate expression cassette, as defined above, in order to allow expression of the heterologous protein/marker in the transgenic animal/recombinant cell line. The meganuclease can be used either as a polypeptide or as a polynucleotide construct encoding said polypeptide. It is introduced into somatic cells 10 of an individual, by any convenient means well-known to those in the art, which are appropriate for the particular cell type, alone or in association with either at least an appropriate vehicle or carrier and/or with the targeting DNA. According to an advantageous embodiment of the uses according to the invention, the meganuclease (polypeptide) is associated with: 15 - liposomes, polyethyleneimine (PEI); in such a case said association is administered and therefore introduced into somatic target cells. - membrane translocating peptides (Bonetta, The Scientist, 2002, 16, 38; Ford et al., Gene Ther., 2001, 8, 1-4 ; Wadia and Dowdy, Curr. Opin. Biotechnol., 2002, 13, 52-56); in such a case, the sequence of the variant/single-chain 20 meganuclease is fused with the sequence of a membrane translocating peptide (fusion protein). According to another advantageous embodiment of the uses according to the invention, the meganuclease (polynucleotide encoding said meganuclease) and/or the targeting DNA is inserted in a vector. Vectors comprising 25 targeting DNA and/or nucleic acid encoding a meganuclease can be introduced into a cell by a variety of methods (e.g., injection, direct uptake, projectile bombardment, liposomes, electroporation). Meganucleases can be stably or transiently expressed into cells using expression vectors. Techniques of expression in eukaryotic cells are well known to those in the art. (See Current Protocols in Human Genetics: Chapter 12 30 "Vectors For Gene Therapy" & Chapter 13 "Delivery Systems for Gene Therapy"). Optionally, it may be preferable to incorporate a nuclear localization signal into the recombinant protein to be sure that it is expressed within the nucleus.
WO 2008/102274 PCT/IB2008/001334 29 Once in a cell, the meganuclease and if present, the vector comprising targeting DNA and/or nucleic acid encoding a meganuclease are imported or translocated by the cell from the cytoplasm to the site of action in the nucleus. For purposes of therapy, the meganucleases and a pharmaceutically 5 acceptable excipient are administered in a therapeutically effective amount. Such a combination is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of the recipient. In the present context, an agent is physiologically significant if its presence 10 results in a decrease in the severity of one or more symptoms of the targeted disease and in a genome correction of the lesion or abnormality. In one embodiment of the uses according to the present invention, the meganuclease is substantially non-immunogenic, i.e., engender little or no adverse immunological response. A variety of methods for ameliorating or eliminating delete 15 rious immunological reactions of this sort can be used in accordance with the inven tion. In a preferred embodiment, the meganuclease is substantially free of N-formyl methionine. Another way to avoid unwanted immunological reactions is to conjugate meganucleases to polyethylene glycol ("PEG") or polypropylene glycol ("PPG") (preferably of 500 to 20,000 daltons average molecular weight (MW)). Conjugation 20 with PEG or PPG, as described by Davis et al. (US 4,179,337) for example, can provide non-immunogenic, physiologically active, water soluble endonuclease conju gates with anti-viral activity. Similar methods also using a polyethylene--poly propylene glycol copolymer are described in Saifer et al. (US 5,006,333). The invention also concerns a prokaryotic or eukaryotic host cell 25 which is modified by a polynucleotide or a vector as defined above, preferably an expression vector. The invention also concerns a non-human transgenic animal or a transgenic plant, characterized in that all or part of their cells are modified by a polynucleotide or a vector as defined above. 30 As used herein, a cell refers to a prokaryotic cell, such as a bacterial cell, or an eukaryotic cell, such as an animal, plant or yeast cell.
WO 2008/102274 PCT/IB2008/001334 30 The subject-matter of the present invention is also the use of at least one meganuclease variant, as defined above, as a scaffold for making other meganucleases. For example a third round of mutagenesis and selection/screening can be performed on said variants, for the purpose of making novel, third generation 5 meganucleases. The different uses of the meganuclease and the methods of using said meganuclease according to the present invention include the use of the I-CreI variant, the single-chain chimeric meganuclease derived from said variant, the poly nucleotide(s), vector, cell, transgenic plant or non-human transgenic mammal 10 encoding said variant or single-chain chimeric meganuclease, as defined above. The I-CreI variant according to the invention may be obtained by a method for engineering I-Crel variants able to cleave a genomic DNA target sequence from the beta-2 microglobulin gene, comprising at least the steps of: (a) constructing a first series of I-CreI variants having at least one 15 substitution in a first functional subdomain of the LAGLIDADG core domain situated from positions 26 to 40 of I-CreI, (b) constructing a second series of I-CreI variants having at least one substitution in a second functional subdomain of the LAGLIDADG core domain situated from positions 44 to 77 of I-CreI, 20 (c) selecting and/or screening the variants from the first series of step (a) which are able to cleave a mutant I-CreI site wherein (i) the nucleotide triplet in positions -10 to -8 of the I-Crel site has been replaced with the nucleotide triplet which is present in positions -10 to -8 of said genomic target and (ii) the nucleotide triplet in positions +8 to +10 has been replaced with the reverse complementary 25 sequence of the nucleotide triplet which is present in positions -10 to -8 of said genomic target, (d) selecting and/or screening the variants from the second series of step (b) which are able to cleave a mutant I-Crel site wherein (i) the nucleotide triplet in positions -5 to -3 of the I-CreI site has been replaced with the nucleotide triplet 30 which is present in positions -5 to -3 of said genomic target and (ii) the nucleotide triplet in positions +3 to +5 has been replaced with the reverse complementary WO 2008/102274 PCT/IB2008/001334 31 sequence of the nucleotide triplet which is present in positions -5 to -3 of said genomic target, (e) selecting and/or screening the variants from the first series of step (a) which are able to cleave a mutant I-CreI site wherein (i) the nucleotide triplet 5 in positions +8 to +10 of the I-CreI site has been replaced with the nucleotide triplet which is present in positions +8 to +10 of said genomic target and (ii) the nucleotide triplet in positions -10 to -8 has been replaced with the reverse complementary sequence of the nucleotide triplet which is present in positions +8 to +10 of said genomic target, 10 (f) selecting and/or screening the variants from the second series of step (b) which are able to cleave a mutant I-CreI site wherein (i) the nucleotide triplet in positions +3 to +5 of the I-CreI site has been replaced with the nucleotide triplet which is present in positions +3 to +5 of said genomic target and (ii) the nucleotide triplet in positions -5 to -3 has been replaced with the reverse complementary 15 sequence of the nucleotide triplet which is present in positions +3 to +5 of said genomic target, (g) combining in a single variant, the mutation(s) in positions 26 to 40 and 44 to 77 of two variants from step (c) and step (d), to obtain a novel homodimeric I-CreI variant which cleaves a sequence wherein (i) the nucleotide 20 triplet in positions -10 to -8 is identical to the nucleotide triplet which is present in positions -10 to -8 of said genomic target, (ii) the nucleotide triplet in positions +8 to +10 is identical to the reverse complementary sequence of the nucleotide triplet which is present in positions -10 to -8 of said genomic target, (iii) the nucleotide triplet in positions -5 to -3 is identical to the nucleotide triplet which is present in positions -5 to 25 -3 of said genomic target and (iv) the nucleotide triplet in positions +3 to +5 is identi cal to the reverse complementary sequence of the nucleotide triplet which is present in positions -5 to -3 of said genomic target, and/or (h) combining in a single variant, the mutation(s) in positions 26 to 40 and 44 to 77 of two variants from step (e) and step (f), to obtain a novel 30 homodimeric I-Crel variant which cleaves a sequence wherein (i) the nucleotide triplet in positions +3 to +5 is identical to the nucleotide triplet which is present in positions +3 to +5 of said genomic target, (ii) the nucleotide triplet in positions -5 to - WO 2008/102274 PCT/IB2008/001334 32 3 is identical to the reverse complementary sequence of the nucleotide triplet which is present in positions +3 to +5 of said genomic target, (iii) the nucleotide triplet in posi tions +8 to +10 of the I-Crel site has been replaced with the nucleotide triplet which is present in positions +8 to +10 of said genomic target and (iv) the nucleotide triplet in 5 positions -10 to -8 is identical to the reverse complementary sequence of the nucleo tide triplet in positions +8 to +10 of said genomic target, (i) combining the variants obtained in steps (g) and (h) to form heterodimers, and (j) selecting and/or screening the heterodimers from step (i) which 10 are able to cleave said genomic DNA target from the beta-2 microglobulin gene. Steps (a), (b), (g), and (h) may comprise the introduction of additional mutations in order to improve the binding and/or cleavage properties of the mutants, particularly at other positions contacting the DNA target sequence or interacting directly or indirectly with said DNA target. This may be performed by 15 generating a combinatorial library as described in the International PCT Application WO 2004/067736. In addition, step (g) and/or (h) may further comprise the introduction of random mutations on the whole variant or in a part of the variant, in particular the C-terminal half of the variant (positions 80 to 163). This may be performed by 20 generating random mutagenesis libraries on a pool of variants, according to standard mutagenesis methods which are well-known in the art and commercially available. The (intramolecular) combination of mutations in steps (g) and (h) may be performed by amplifying overlapping fragments comprising each of the two subdomains, according to well-known overlapping PCR techniques. 25 The (intermolecular) combination of the variants in step (i) is performed by co-expressing one variant from step (g) with one variant from step (h), so as to allow the formation of heterodimers. For example, host cells may be modified by one or two recombinant expression vector(s) encoding said variant(s). The cells are then cultured under conditions allowing the expression of the variant(s), so that 30 heterodimers are formed in the host cells, as described previously in the International PCT Application WO 2006/097854 and Arnould et al., J. Mol. Biol., 2006, 355, 443 458.
WO 2008/102274 PCT/IB2008/001334 33 The selection and/or screening in steps (c), (d), (e), (f) and/or (j) may be performed by using a cleavage assay in vitro or in vivo, as described in the International PCT Application WO 2004/067736, Arnould et al., J. Mol. Biol., 2006, 355, 443-458, Epinat et al., Nucleic Acids Res., 2003, 31, 2952-2962 and Chames et 5 al., Nucleic Acids Res., 2005, 33, e178. According to another advantageous embodiment of said method, steps (c), (d), (e), (f) and/or (j) are performed in vivo, under conditions where the double-strand break in the mutated DNA target sequence which is generated by said variant leads to the activation of a positive selection marker or a reporter gene, or the 10 inactivation of a negative selection marker or a reporter gene, by recombination mediated repair of said DNA double-strand break. The subject matter of the present invention is also an I-CreI variant having mutations in positions 26 to 40 and/or 44 to 77 of I-Crel that is useful for engineering the variants able to cleave a DNA target from the beta-2 microglobulin 15 gene, according to the present invention. In particular, the invention encompasses the I-CreI variants as defined in step (c) to (f) of the method for engineering I-Crel variants, as defined above, including the variants of the sequence SEQ ID NO: 78, 79, 80, 81 and 105. The invention encompasses also the I-Crel variants as defined in step (g) and (h) of the method for engineering I-Crel variants, as defined above, including 20 the variants of the sequence SEQ ID NO: 29 to 36. Single-chain chimeric meganucleases able to cleave a DNA target from the gene of interest are derived from the variants according to the invention by methods well-known in the art (Epinat et al., Nucleic Acids Res., 2003, 31, 2952-62; Chevalier et al., Mol. Cell., 2002, 10, 895-905; Steuer et al., Chembiochem., 2004, 5, 25 206-13; International PCT Applications WO 03/078619 and WO 2004/031346). Any of such methods, may be applied for constructing single-chain chimeric meganucleases derived from the variants as defined in the present invention. The polynucleotide sequence(s) encoding the variant as defined in the present invention may be prepared by any method known by the man skilled in the 30 art. For example, they are amplified from a cDNA template, by polymerase chain reaction with specific primers. Preferably the codons of said cDNA are chosen to favour the expression of said protein in the desired expression system.
WO 2008/102274 PCT/IB2008/001334 34 The recombinant vector comprising said polynucleotides may be obtained and introduced in a host cell by the well-known recombinant DNA and genetic engineering techniques. The I-CreI variant or single-chain derivative as defined in the 5 present the invention are produced by expressing the polypeptide(s) as defined above; preferably said polypeptide(s) are expressed or co-expressed (in the case of the variant only) in a host cell or a transgenic animal/plant modified by one expression vector or two expression vectors (in the case of the variant only), under conditions suitable for the expression or co-expression of the polypeptide(s), and the variant or single-chain 10 derivative is recovered from the host cell culture or from the transgenic animal/plant. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for 15 example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. 20 J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols. 154 and 25 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 30 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
WO 2008/102274 PCT/IB2008/001334 35 In addition to the preceding features, the invention further comprises other features which will emerge from the description which follows, which refers to examples illustrating the I-Crel meganuclease variants and their uses according to the invention, as well as to the appended drawings in which: 5 - figure 1 illustrates gene targeting strategies (a) A linear sequence containing a marker surrounded by sequences homologous to the targeted locus can be introduced into the nucleus, and recombine with the homologous targeted locus. This experimental design is today the most widespread one for gene knock-in and gene knock-out. Note that the insertion of the marker can be associated with a deletion 10 within the targeted locus, resulting in gene replacement. (b) meganuclease-induced gene targeting. In this case, the targeting sequence is often part of a circular plasmid. - figure 2 represents the tridimensional structure of the I-CreI homing endonuclease bound to its DNA target. The catalytic core is surrounded by two a4cpa folds forming a saddle-shaped interaction interface above the DNA 15 major groove. - figure 3 illustrates the combinatorial approach for the making of redesigned Homing Endonucleases. A large collection of I-CreI derivatives with locally altered specificity is generated. Then, a two step combinatorial approach is used to assemble these mutants into homodimeric proteins (by combinations of 20 mutations within a same monomer), and then into heterodimers, resulting in meganucleases with fully redesigned specificity. - figure 4 represents the human B2M gene (accession number NC_000015 ; 6673 pb). The Exons are boxed (Exon 1: positions 1-127; Exon 2: positions 3937 to 4215; Exon 3: 4843 to 4870; Exon 4: positions 6121 to 6673). The 25 ORF is from position 61 (Exon 1) to positions 4856 (Exon 3). Various meganuclease sites (B2Mn) are indicated. - figure 5 represents the B2M series of target. B2Ml 1.2 and B2M1 1.3 are two palindromic sequences derived from the B2M target by mirror duplication of one half of the target. These two targets can in turn be considered as 30 combinations of the 1 OGAAP and 5TAGP (B2M 11.2) and the 1 OCTGP and the 5TTTP targets (B2M1 1.3) found to be cleaved by I-CreI targets, if nucleotides at positions ±11, ±7 and ±6 in the B2Ml 1.2 and B2M1 1.3 targets are considered as WO 2008/102274 PCT/IB2008/001334 36 having no impact on cleavage. All targets are aligned with the C1221 target, a palindromic sequence cleaved by I-CreI. - figure 6 represent three strategies for inactivation of a gene by meganuclease-induced recombination. Note that in all three cases, both homologous 5 chromosomes have to be targeted in order to totally inactivate the function of the gene. (a) inactivation by cleavage in the intron: a transcription termination sequence (polyA1) and a marker cassette including a promoter, the marker ORF, and a second transcription termination sequence (polyA2). The transcription termination sequences will result in a truncated transcript, and therefore, a truncated protein. (b) Inactivation 10 by cleavage in an exon, and knock-in of a marker cassette. Marker knock-in can be associated with deletion of exonic sequences (see Figure 1). (c) Inactivation by cleavage in an exon, and repair by the error-prone Non Homologous End Joining pathway. In the absence of a repair matrix, the DNA double-strand break will be repaired essentially by NHEJ, resulting most of the time in perfect rejoining of the 3' 15 cohesive ends resulting from meganuclease cleavage. In this case, the restored cleavage site can be cleaved again by the meganuclease. However, this error prone repair pathway can also result in small deletions (a few nucleotides), that will inactivate the cleavage site, and result in frameshift mutation. - figure 7 illustrates the cleavage of the B2M1 1.2 target by 20 combinatorial mutants. The figure displays an example of primary screening of I-CreI combinatorial mutants with the B2M1 1.2 target. H12 is a positive control (C). In the first top filter, the sequence of positive mutant at position B3 (circle) is KNAHQS/AYSYK (same nomenclature as for Table I). In the second filter, bottom one's, the sequence of positive mutant at position F7 is KNGHQS/AYSYK. 25 - figure 8 illustrates cleavage of the of B2M 11.2 target by optimized mutants. A series of I-CreI N75 optimized mutants cutting B2M 11.2 are obtained from random mutagenesis of the mutants KNAHQS/AYSYK and KNGHQS/AYSYK. Cleavage is tested with the B2M 11.2 target. Mutants cleaving B2M 11.2 are circled. For example, the sequence of positive mutant at position B3 is corresponding to 30 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C (same nomenclature as for Table II). H12 is a positive control.
WO 2008/102274 PCT/IB2008/001334 37 - figure 9 illustrates cleavage of the B2Ml 1.3 target by combinatorial mutants. The figure displays an example of primary screening of I-CreI combinatorial mutants with the B2M 11.3 target. H10, H 11 and H12 are respectively negative (Cl) and two positive controls (C2 and C3) of different strength. In the filter, 5 the sequence of positive mutant at position G5 (circle) is KQSGCS/QNSNR (same nomenclature as for Table III). - figure 10 illustrates cleavage of B2M 11 target by heterodimeric combinatorial mutants. The figure displays primary screening of combinations of I CreI mutants with the B2M 11 target. A column of positive heterodimeric 10 combinatorial mutants are circled. In the example filter, (1) and (2) are yeast strain with B2Ml 1 target and mutant respectively 28K30N32G33H38Q40S44A68Y70S75Y77K/2196R105A (1) and 28K30N32A33H38Q40S44A68Y70S75Y77K/132V (2), matted with the yeast strain with 28K30Q32S33G38C40S44Q68N70S75N77R (Ml) (same nomenclature as for 15 Table IV). - figure 11 illustrates cleavage of B2Ml 1 target by optimized heterodimeric combinatorial mutants. A series of I-CreI N75 optimized mutants cutting B2M 11.3 are coexpressed with mutants cutting B2M 1l.2. Cleavage is tested with the B2Mll target. Mutants cleaving B2Ml1 are circled (as example G9, 20 corresponding to an heterodimer of 28K30Q32S33G38C40S44Q68N70S75N77R vs 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C. In the examples filter, the yeast strain with B2Ml l target and mutant 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C is matted with the yeast strain with 28K30Q32S33G38C40S44Q68N70S75N77R (MI) (same nomenclature as 25 for Table V), or controls (Cl to C3) in diagonal. H1O, HI1 and H12 are also respectively negative (Cl) and two positive controls (C2 and C3) of different strength. - figure 12 represents the pCLS 1055 vector map. - figure 13 represents the pCLS0542 vector map. - figure 14 represents the pCLS 1107 vector map. 30 - figure 15 represents meganuclease target sequences found in the human B2M gene and the corresponding I-CreI variant which is able to cleave said DNA target. The exons closest to the target sequences, and the exons junctions are WO 2008/102274 PCT/IB2008/001334 38 indicated (columns 2 and 3), the sequence of the DNA target is presented (column 4), with its position (column 5). The minimum repair matrix for repairing the cleavage at the target site is indicated by its first nucleotide (start, column 8) and last nucleotide (end, column 9). The sequence of each variant is defined by the mutated residues at 5 the indicated positions. For example, the first heterodimeric variant of figure 15 consists of a first monomer having K, N, S, R, A, S, D, A, S, K, R in positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77, respectively and a second monomer having R, N, S, A, Y, Q, A, Y, S, Y and K in positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77, respectively. The positions are indicated by reference to I-CreI sequence 10 SWISSPROT P05725 (SEQ ID NO: 1); I-CreI has K, N, S, Y, Q, S, Q, R, R, D and I, in positions 28, 30, 32, 33, 38, 40, 44, 68, 70, 75 and 77 respectively. - figure 16 represents the pCLS 1069 vector map. - figure 17 represents the pCLS 1058 vector map. - figure 18 represents the B2M18 series of target. B2M18.3 and 15 B2M18.4 are two palindromic sequences derived from the B2M18 target by mirror duplication of one half of the target. These two targets can in turn be considered as combinations of 1 ONNN and 5NNN targets found to be cleaved by I-CreI targets, if one considers that nucleotides at positions +11, +7 and +6 in the B2M18.3 and B2M18.4 targets have no impact on cleavage. All targets are aligned with the C1221 20 target, a palindromic sequence cleaved by I-Crel. - figure 19 illustrates cleavage of the B2M18.4 target by combinatorial mutants. The figure displays an example of primary screening of I-CreI combinatorial mutants with the B2M18.4 target. Right double dots (C) on each quarter are alternatively respectively negative (Cl) and two positive controls (C2 and C3) of 25 different strength. The left double dots (M) in the filter are combinatorial clone tested. The sequence of positive mutant at position B 10 (circle) is KNGCQS/QYSRQ (same nomenclature as for Table VII). - figure 20 represents the B2M20 series of target. B2M20.3 and B2M20.4 are two palindromic sequences derived from the B2M20 target by mirror 30 duplication of one half of the target. These two targets can in turn be considered as combinations of 1ONNN and 5NNN targets found to be cleaved by I-CreI targets, if one considers that nucleotides at positions +11, ±7 and +6 in the B2M20.3 and WO 2008/102274 PCT/IB2008/001334 39 B2M20.4 targets have no impact on cleavage. All targets. are aligned with the C1221 target, a palindromic sequence cleaved by I-CreI. - figure 21 illustrates cleavage of the B2M20.4 target by combinatorial mutants. The figure displays an example of primary screening of I-CreI 5 combinatorial mutants with the B2M20.4 target. Right double dots (C) on each quarter are alternatively respectively negative (Cl) and two positive controls (C2 and C3) of different strength. The left double dots (M) in the filter are combinatorial clone tested. The sequence of positive mutant at position F6 (circle) is KNSTQE/QRRDI (same nomenclature as for Table VIII). 10 Example 1: Strategy for engineering novel meganucleases cleaving the human B2M gene The combinatorial approach described in Smith et al., Nucleic Acids Res., 2006 and illustrated in figure 3, was used to engineer the DNA binding domain of I-CreI, and cleave one of the B2M targets, B2M 11 (figures 5 and 15), a 24 bp (non 15 palindromic) target (figure 5) located at positions 2892 to 2915 of the human B2M gene (accession number NC_000015.8, positions 42790977 to 42797649). The meganucleases cleaving B2M 1I can be used to inactivate the B2M gene by insertion of a transcription termination signal that will interrupt the transcription, and result in a truncated protein (Figure 6a). 20 The B2Mll sequence is partly a patchwork of the 1OGAA_P, 1 OCTG_P, 5TAGP and 5TTTP targets (Figure 5), which are cleaved by previously identified meganucleases, obtained as described in International PCT Applications WO 2006/097784, WO 2006/097853; Arnould et al., J. Mol. Biol., 2006, 355, 443 458 and Smith et al., Nucleic Acids Res., 2006, 34, e149. Thus B2Mll could be 25 cleaved by meganucleases combining the mutations found in the I-CreI derivatives cleaving these four targets. The 1OGAA_P, 1OCTG_P, 5TAGP and 5TTTP sequences are 24 bp derivatives of C 1221, a palindromic sequence cleaved by I-Crel (International PCT Applications WO 2006/097784, WO 2006/097853; Arnould et al., J. Mol. Biol., 2006, 30 355, 443-458 and Smith et al., Nucleic Acids Res., 2006, 34, e149). However, the structure of I-CreI bound to its DNA target suggests that the two external base pairs of these targets (positions -12 and 12) have no impact WO 2008/102274 PCT/IB2008/001334 40 on binding and cleavage (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B.S. and Stoddard B.L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269), and in this study, only positions 11 to 11 were considered. Consequently, the B2M 11 series of targets were defined as 5 22 bp sequences instead of 24 bp. Two palindromic targets, B2M1 1.2 and B2Ml 1.3 were derived from B2Mll (Figure 5). Since B2M11.2 and B2M11.3 are palindromic, they should be cleaved by homodimeric proteins. Thus, proteins able to cleave the B2Ml 1.2 and B2M 11.3 sequences as homodimers, were first designed (examples 2 and 3), followed 10 by an optimization of homodimers able to cleaved more efficiently B2M 11.2 target (example 4), and then coexpression to obtain heterodimers cleaving B2M11.1 (example 5). Chosen mutant cleaving B2M 11.3 were then refined; the chosen mutants were randomly mutagenized, and used to form novel heterodimers that were screened against the B2M 11 target (example 6). 15 Example 2: Making of meganucleases cleaving B2M11.2 This example shows that I-Crel mutants can cut the B2M1 1.2 DNA target sequence derived from the left part of the B2Ml l target in a palindromic form (figure 5). Target sequences described in this example are 22 bp palindromic 20 sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix _P. For example, target B2Ml 1.2 will be noted also tgaaattaggtP; SEQ ID NO: 96)). B2M1 1.2 is similar to 5TAGP in positions ±1, ±2, ±3, +4, +5 and +7 and to 1OGAAP in positions ±1, +2, ±7, +8, +9 and +10. It was hypothesized that 25 positions +6 and +11 would have little effect on the binding and cleavage activity. Mutants able to cleave 5TAGP target (caaaactaggt_P; SEQ ID NO: 94) were previously obtained by mutagenesis on I-CreI N75 at positions 44, 68, 70, 75 and 77, as described in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784, WO 2006/097853. Mutants able to cleave the 30 10GAAP target (cgaaacgtcgt _P; SEQ ID NO:92 ) were obtained by mutagenesis on I-Crel N75 and D75 at positions 28, 30, 32, 33, 38, 40, as described previously in WO 2008/102274 PCT/IB2008/001334 41 Smith et al, Nucleic Acids Res., 2006, 34, e149). Thus combining such pairs of mutants would allow for the cleavage of the B2M 11.2 target. Therefore, to check whether combined mutants could cleave the B2M 11.2 target, mutations at positions 44, 68, 70, 75 and 77 from proteins cleaving 5 5TAGP (caaaactaggtP; SEQ ID NO: 94) were combined with the 28, 30, 32, 33, 38 and 40 mutations from proteins cleaving 1OGAAP (cgaaacgtcgtP; SEQ ID NO: 92). 1) Material and Methods The method for producing meganuclease variants and the assays based on cleavage-induced recombination in mammal or yeast cells, which are used 10 for screening variants with altered specificity are described in the International PCT Application WO 2004/067736; Epinat et al., Nucleic Acids Res., 2003, 31, 2952 2962; Chames et al., Nucleic Acids Res., 2005, 33, e178, and Arnould et al., J. Mol. Biol., 2006, 355, 443-458. These assays result in a functional LacZ reporter gene which can be monitored by standard methods. 15 a) Construction of target vector The target was cloned as follow: oligonucleotide corresponding to the target sequence flanked by gateway cloning sequence was ordered from PROLIGO: 5' tggcatacaagttttgttctcaggtacctgagaacaacaatcgtctgtca 3' (SEQ ID NO: 98). Double stranded target DNA, generated by PCR amplification of the single stranded 20 oligonucleotide, was cloned using the Gateway protocol (INVITROGEN) into yeast reporter vector (pCLS1055, Figure 12). Yeast reporter vector was transformed into S. cerevisiae strain FYBL2-7B (MAT a, ura3A851, trp1 A63, leu2AJ, lys2A202). b) Construction of combinatorial mutants I-CreI mutants cleaving 1OGAAP or 5TAGP were identified as 25 described previously in Smith et al, Nucleic Acids Res., 2006, 34, e149, and Arnould et al., J. Mol. Biol., 2006, 355, 443-458; International PCT Applications WO 2006/097784, WO 2006/097853, respectively for the 1OGAAP or 5TAG P targets. In order to generate I-CreI derived coding sequence containing mutations from both series, separate overlapping PCR reactions were carried out that amplify the 5' end (aa 30 positions 1-43) or the 3' end (positions 39-167) of the I-CreI coding sequence. For both the 5' and 3' end, PCR amplification is carried out using GallOF (5' gcaactttagtgctgacacatacagg-3'; SEQ ID NO: 99) or GallOR (5'- WO 2008/102274 PCT/IB2008/001334 42 acaaccttgattggagacttgacc-3'; SEQ ID NO: 100) primers specific to the vector (pCLS0542, Figure 13) and primers specific to the I-Crel coding sequence for amino acids 3 9-43 (assF 5'-ctannnttgaccttt-3'(SEQ ID NO: 101 ) or assR 5'-aaaggtcaannntag 3'(SEQ ID NO: 102)) where nnn code for residue 40. The PCR fragments resulting 5 from the amplification reaction realized with the same primers and with the same coding sequence for residue 40 were pooled. Then, each pool of PCR fragments resulting from the reaction with primers GallOF and assR or assF and GallOR was mixed in an equimolar ratio. Finally, approximately 25 ng of each final pool of the two overlapping PCR fragments and 75 ng of vector DNA (pCLS0542) linearized by 10 digestion with NcoI and EagI were used to transform the yeast Saccharomyces cerevisiae strain strain FYC2-6A (MATa, trplA63, leuAl, his3A200) using a high efficiency LiAc transformation protocol (Gietz and Woods, Methods Enzymol., 2002, 350, 87-96). An intact coding sequence containing both groups of mutations is generated by in vivo homologous recombination in yeast. 15 c) Mating of meganuclease expressing clones and screening in yeast: Screening was performed as described previously (Arnould et al., J. Mol. Biol., 2006, 355, 443-458). Mating was performed using a colony gridder (QpixII, Genetix). Mutants were gridded on nylon filters covering YPD plates, using a low gridding density (about 4 spots/cm 2 ). A second gridding process was performed 20 on the same filters to spot a second layer consisting of different reporter-harboring yeast strains for each target. Membranes were placed on solid agar YPD rich medium, and incubated at 30 *C for one night, to allow mating. Next, filters were transferred to synthetic medium, lacking leucine and tryptophan, with galactose (2 %) as a carbon source, and incubated for five days at 37 *C, to select for diploids carrying the 25 expression and target vectors. After 5 days, filters were placed on solid agarose medium with 0.02 % X-Gal in 0.5 M sodium phosphate buffer, pH 7.0, 0.1 % SDS, 6 % dimethyl formamide (DMF), 7mM p-mercaptoethanol, 1% agarose, and incubated at 37 *C, to monitor P-galactosidase activity. Results were analyzed by scanning and quantification was performed using appropriate software. 30 d) Sequencing of mutants To recover the mutant expressing plasmids, yeast DNA was extracted using standard protocols and used to transform E. coli. Sequence of mutant ORF were WO 2008/102274 PCT/IB2008/001334 43 then performed on the plasmids by MILLEGEN SA. Alternatively, ORFs were amplified from yeast DNA by PCR (Akada et al., Biotechniques, 2000, 28, 668-670), and sequence was performed directly on PCR product by MILLEGEN SA. 2) Results 5 I-Crel combinatorial mutants were constructed by associating mutations at positions 44, 68, 70, 75 and 77 with the 28, 30, 33, 38 and 40 mutations on the I-CreI N75 or D75 scaffold, resulting in a library of a complexity of 2014. Examples of combinations are displayed on Table 1. These libraries were transformed into yeast and 4464 clones (2.2 times the diversity) were screened for cleavage against 10 B2Ml 1.2 DNA target (tgaaattaggt _P; SEQ ID NO: 96). 2 positives clones were found with a very low level of activity, which after sequencing and validation by secondary screening turned out to correspond to 2 different novel endonucleases (see Table I). Positives are shown in Figure 7. Throughout the text and figures, combinatorial mutants sequences are 15 named with an eleven letter code, after residues at positions 28, 30, 32, 33, 38, 40, 44, 68 and 70, 75 and 77. For example, KNGHQS/AYSYK stands for I-CreI K28, N30, G32, H33, Q38, S40, A44, Y68, S70, Y75 and K77 (I-CreI 28K30N32G33H38Q40S44A68Y70S75Y77K). Parental mutants are named with a six letter code, after residues at positions 28, 30, 32, 33, 38 and 40 or a five letter code, 20 after residues at positions 44, 68, 70, 75 and 77. For example, KNGHQS stands for I CreI K28, N30, G32, H33, Q38 and S40, and AYSYK stands for I-CreI A44, Y68, S70, Y75 and K77. 25 30 WO 2008/102274 PCT/IB2008/001334 44 Table I: Cleavage of the B2M11. 2 target by the combinatorial variants Amino acids at positions Amino acids at positions 28,30, 32,33,38 and 40 44,68,70,75 (KNGHQS stands for K28, N30, G32, H33, Q38 and S40) and 77 (AYSYK stands for A44, Y68, S70, Y75 and K77) KNGHQS KNAHQS KNSHQS KNAQQS KYSHQS KNPRQS KPSHQS KRSWQS (SEQ ID (SEQ ID NO: 79) NO: 80) ARSYY ANNNI SRSYT AYSYK + + (SEQ ID No: 78) AQNNI ARSYV NRSYN ARNNI ARTNI AKSYI NYSYV ARSYQ SRSYS NQSSV NRSYS AKSYR TRSYI TNSYK ARSYN SRSYI ARSYI TYSYK NRSNI NRSYI ATNNI *Only 176 out of the 2014 combinations are displayed + indicates cleavage of the B2M 11.2 target by the combinatorial variant Example 3: Making of meganucleases cleaving B2M11.2 with higher efficacy by 5 random mutagenesis of meganucleases cleaving B2M11.2. I-Crel mutants able to cleave the palindromic B2M 11.2 target have been identified by assembly of mutants cleaving the palindromic 1OGAAP and 5TAGP target (example 2). However, only 2 of these combinations were able to cleave B2M 11.2 and with a minimal efficiency. 10 Therefore the two protein combinations cleaving B2M 11.2 were mutagenized and variants cleaving B2M 11.2 with better efficiency were screened. According to the structure of the I-CreI protein bound to its target, there is no contact between the residues used for the first combinatorial approach (28, 30, 32, 33, 38 and 40 vs 44, 68, 70, 75 and 77) in the I-CreI protein (Chevalier et al., Nat. Struct. Biol., WO 2008/102274 PCT/IB2008/001334 45 2001, 8, 312-316; Chevalier B.S. and Stoddard B.L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al, J. Mol. Biol., 2003, 329, 253-269). Thus, it is difficult to rationally choose a set of positions to mutagenize, and mutagenesis was done on the C-terminal part of the protein (83 last amino acids) or on the whole protein. 5 1) Material and Methods Random mutagenesis libraries were created on a pool of chosen mutants, by PCR using Mn 2 or derivatives of dNTPs as 8-oxo-dGTP and dPTP in two-step PCR process, as described in the protocol from JENA BIOSCIENCE GmbH in JBS dNTP-Mutagenis kit. Primers used are preATGCreFor (5' 10 gcataaattactatacttctatagacacgcaaacacaaatacacagcggccttgccacc-3'; SEQ ID NO: 103) and ICrelpostRev (5'-ggctcgaggagctcgtctagaggatcgctcgagttatcagtcggccgc-3'; SEQ ID NO: 104). The new libraries were cloned in vivo in the yeast in the linearized kanamycin vector harbouring a galactose inducible promoter, a KanR as selectable marker and a 2 micron origin of replication. Positives resulting clones were verified 15 by sequencing (MILLEGEN). Pools of mutants were amplified by PCR reaction using these primers common for leucine vector (pCLS0542, Figure 13) and kanamycin vector (pCLS 1107, Figure 14). Approximately 75ng of PCR fragment and 75ng of vector DNA (pCLS0542) linearized by digestion with NcoI and EagI are used to transform the 20 yeast Saccharomyces cerevisiae strain FYC2-6A (MATa, trp1A63, leu2Al, his3A200) using a high efficiency LiAc transformation protocol. A library of intact coding sequence for the I-CreI mutant is generated by in vivo homologous recombination in yeast. Mating assays were done as described in example 2. 25 2) Results: Two mutants cleaving B2M 11.2, I-CreI 28K30N32G33H38Q40S44A68Y70S75Y77K and I-CreI 28K30N32A3338Q40SH44A68Y70S75Y77K, also called KNGHQS/AYSYK and KNAHQS/AYSYK according to nomenclature of Table I) were pooled, randomly 30 mutagenized and transformed into yeast (Figure 13). 4464 transformed clones were then mated with a yeast strain that contains the B2M 11.2 target in a reporter plasmid. Thirty-two clones were found to trigger cleavage of the B2Ml 1.2 target when mated WO 2008/102274 PCT/IB2008/001334 46 with such yeast strain, corresponding at least to 13 different novel endonucleases (see Table II). Example of positives is shown on Figure 8. Table II: Optimized mutants towards the B2M11.2 target Optimized Mutant B2M1 1.2* Target (SEQ ID NO: 24 to 36) B2M1 1.2 I-Crel 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R + I-Crel 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C 1-Crel 28K30N32A33H 38Q40S44A68Y70S75Y77K/132V + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/2196R105A + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/120G + I-Crel 28K30N32A33H38Q40S44A68Y70S75Y77K/43L105A159R + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/50R |-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/49A50R + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/81V129A154G + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/129A161P + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/117G + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/81T + I-Crel 28K30N32G33H38Q40S44A68Y70S75Y77K/103T + B2M 11.2 target cleavage 5 * optimized mutations are in bold Example 4: Making of meganucleases cleaving B2M11.3 This example, shows that I-CreI mutants can cleave the B2M1 1.3 DNA target sequence derived from the right part of the B2M11.1 target in a palindromic form (Figure 5). All target sequences described in this example are 22 bp 10 palindromic sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix _P, solely to indicate that (for example, B2M1 1.3 will be called tctgactttgtP; SEQ ID NO: 97). B2M11.3 is similar to 5TTTP in positions ±1, ±2, ±3, ±4, ±5, ±6 and ±7 and to 1OCTGP in positions ±1, ±2, ±6, ±7, ±8, ±9 and ±10. It was 15 hypothesized that position ± 11 would have little effect on the binding and cleavage activity. Mutants able to cleave 5TTTP target (caaaactttgt_P; SEQ ID NO: 95) were previously obtained by mutagenesis on I-CreI N75 at positions 44, 68, 70, 75 and 77, as described in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784, WO 2006/097853. Mutants able to cleave the 20 1OCTGP target (cctgacgtcgtP; SEQ ID NO: 93) were obtained by mutagenesis on I CreI N75 and D75 at positions 28, 30, 32, 33, 38, 40 and 70, as described in Smith et al., Nucleic Acids Res., 2006, 34, e149). Thus combining such pairs of mutants would allow for the cleavage of the B2M 11.3 target. Both sets of proteins are mutated at position 70. However, it was 25 previously demonstrated that two separable functional domains exist in I-CreI (Smith WO 2008/102274 PCT/IB2008/001334 47 et al., Nucleic Acids Res., 2006, 34, e149). That implies that this position has little impact on the specificity in base 10 to 8 of the target. Therefore, to check whether combined mutants could cleave the B2M 11.3 target, mutations at positions 44, 68, 70, 75 and 77 from proteins cleaving 5TTTP (caaaactttgtP; SEQ ID NO: 95) were 5 combined with the 28, 30, 32, 33, 38, 40 mutations from proteins cleaving 1 OCTG_P (cctgacgtcgtP; SEQ ID NO: 93). 1) Material and Methods I-Crel mutants cleaving 1OCTGP or 5TTTP were identified as described previously in Smith et al, Nucleic Acids Res., 2006, 34, e149, and Arnould 10 et al., J. Mol. Biol., 2006, 355, 443-458; International PCT Applications WO 2006/097784, WO 2006/097853, respectively for the 1OCTGP and 5TTTP targets. In order to generate I-CreI derived coding sequence containing mutations from both series, separate overlapping PCR reactions were carried out that amplify the 5' end (aa positions 1-43) or the 3' end (positions 39-167) of the I-CreI 15 coding sequence. For both the 5' and 3' end, PCR amplification is carried out using GallOF (5'-gcaactttagtgctgacacatacagg-3': SEQ ID NO: 99) or GallOR (5' acaaccttgattggagacttgacc-3': SEQ ID NO: 100) primers specific to the vector (pCLS0542, Figure 13) and primers specific to the I-CreI coding sequence for amino acids 39-43 (assF 5'-ctannnttgaccttt-3'(SEQ ID NO: 101) or assR 5'-aaaggtcaannntag 20 3'(SEQ ID NO: 102)) where nnn code for residue 40. The PCR fragments resulting from the amplification reaction realized with the same primers and with the same coding sequence for residue 40 were pooled. Then, each pool of PCR fragments resulting from the reaction with primers Gall1F and assR or assF and GallOR was mixed in an equimolar ratio. Finally, approximately 25ng.of each final pool of the two 25 overlapping PCR fragments and 75ng of vector DNA, a kanamycin resistant yeast expression vector (pCLS 1107, Figure 14), linearized by digestion with DraIII and NgoMIV were used to transform the yeast Saccharomyces cerevisiae strain strain FYC2-6A (MATa, trplA63, leu2Al, his3A200) using a high efficiency LiAc transformation protocol (Gietz and Woods, methods Enzymol., 2002, 350, 87-96). An 30 intact coding sequence containing both groups of mutations is generated by in vivo homologous recombination in yeast.
WO 2008/102274 PCT/IB2008/001334 48 2) Results I-Crel combinatorial mutants were constructed by associating mutations at positions 44, 68, 70, 75 and 77 with the 28, 30, 33, 38 and 40 mutations on the I-CreI N75 or D75 scaffold, resulting in a library of complexity 1600. Examples of combinatorial 5 mutants are displayed on Table III. This library was transformed into yeast and 3348 clones (2.1 times the diversity) were screened for cleavage against B2M 11.3 DNA target (tctgactttgtP; SEQ ID NO: 97). One positive clone was found, which after sequencing and validation by secondary screening turned out to be correspond to a novel endonuclease (see Table III). Positive is shown in Figure 9. 10 Table III: Cleavage of the B2M11.3 target by the combinatorial mutants* Amino acids at positions Amino acids at positions 28, 30,32, 33,38 and 40 44,68,70, (KNSTQA stands for K28, N30, S32, T33, Q38 and A40) 75 and 77 (KNANI stands for K44, N68, ____ A70, N75 KQSGCS and 177) KNSTQA (SEQ ID KNSGQA KNSSQP KDSRGS KSSNQS KNTTQS KNSGCS KQSTQS KCSGQS NO: 81) KNANI' KRDNI QNSNR QRDNI KGSNI NHNNI THHNI KNSNI QRRNI QRSDK KASNT QESNR TRSYI TSSKN QRSNT TYSYR QASDR KYSNI KYSNQ TTSYR KQSNT QNSNR + (SEQ ID NO: 105) QSSNR KYSDT TYSYK * Only 240 out of the 1600 combinations are displayed). + indicates cleavage of the B2M 11.3 target by the combinatorial mutant. Example 5: Making of meganucleases cleaving B2M11 by coexpression of meganucleases cleaving B2M11.2 assembly with proteins cleaving B2M11.3 15 I-CreI mutants able to cleave each of the palindromic B2M 11 derived targets (B2M1 1.2 and B2M1 1.3) were identified in examples 2, 3 and 4. Pairs of such WO 2008/102274 PCT/IB2008/001334 49 mutants (one cutting B2M 11.2 and one cutting B2M 11.3) were co-expressed in yeast Upon coexpression, there should be three active molecular species, two homodimers, and one heterodimer. It was assayed whether the heterodimers that should be formed cut the B2M 11 target. 5 1) Material and Methods a) Cloning of optimized mutants in leucine vector, in B2M 11 target yeast The yeast strain FYBL2-7B (MAT a, ura3A851, trp1A63, leu2A1, lys2A202) containing the B2M 11 target into yeast reporter vector (pCLS 1055, Figure 12) is transformed with optimised mutants cutting B2M 11.2 target that were cloned in 10 leucine vector (pCLS0542, Figure 13), using a high efficiency LiAc transformation protocol. Mutant-target yeasts are used as target for mating assays as described in examples 2 and 4, against the mutant cutting B2M 1.3, in kanamycin vector (pCLS 1107). b) Mating of meganucleases coexpressing clones and screening in yeast 15 Mating was performed using a colony gridder (QpixII, Genetix). Mutants were gridded on nylon filters covering YPD plates, using a low gridding density (about 4 spots/cm2). A second gridding process was performed on the same filters to spot a second layer consisting of different reporter-harbouring yeast strains for each mutant-target. Membranes were placed on solid agar YPD rich medium, and 20 incubated at 30*C for one night, to allow mating. Next, filters were transferred to synthetic medium, lacking leucine and tryptophan, adding G418, with galactose (1 %) as a carbon source, and incubated for five days at 37 'C, to select for diploids carrying the expression and target vectors. After 5 days, filters were placed on solid agarose medium with 0.02 % X-Gal in 0.5 M sodium phosphate buffer, pH 7.0, 0.1 % SDS, 6 25 % dimethyl formamide (DMF), 7mM P-mercaptoethanol, 1% agarose, and incubated at 37 *C, to monitor p-galactosidase activity. Results were analyzed by scanning and quantification was performed using appropriate software 2) Results: Coexpression of mutants cleaving the B2Ml 1.2 and B2M1 1.3 30 resulted in the cleavage of the B2M 11 target in most cases (Figure 10). Functional combinations are summarized in Table IV.
WO 2008/102274 PCT/IB2008/001334 50 Table IV: Combinations that resulted in cleavage of B2M1 1 target. B2MI1 Mutant B2M11.3 Optimized Mutant B2M11.2 target cleavage I-Crel 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C + I-Crel 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R + I-Crel 28K30N32A33H38Q40S 44A68Y70S75Y77K/1 32V + I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/2196R105A + I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/120G + I-Crel 1-Crel 28K30N32A33H38Q40S 44A68Y70S75Y77K/43L1 05A1 59R K28Q30S32G33C38S40 1-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/50R Q44N68S70N75R77 |-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/49A50R (KQSGCS/QNSNR) I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/81V129A154G I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/129A161P l-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/11 7G I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/81T I-Crel 28K30N32G33H38Q40S 44A68Y70S75Y77K/103T + indicates that the heterodimeric mutant is cleaving the B2M 11 target Example 6: Making of meganucleases cleaving B2M11 with higher efficacy by random mutagenesis of meganuclease cleaving B2M11.3 and co-expression with 5 proteins cleaving B2M11.2 I-CreI mutants able to cleave the palindromic B2Mll target were identified by co-expression of mutants cleaving the palindromic B2Ml1.2 and B2M11.3 targets (Example 5). However, efficiency and number of positive combinations able to cleave B2M1 1 were minimal. 10 Therefore, the protein cleaving B2Ml1.3 was mutagenized and variants cleaving B2M1 1 with better efficiency, when combined to optimized mutants for B2M 11.2, were screened. According to the structure of the I-CreI protein bound to its target, there is no contact between the residues used for the first combinatorial approach (28, 30, 32, 33, 38 and 40 vs 44, 68, 70, 75 and 77) in the I-CreI protein 15 (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B.S. and Stoddard B.L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269). Thus, it is difficult to rationally choose a set of positions to mutagenize, and mutagenesis was done on the C-terminal part of the protein (83 last amino acids) or on the whole protein. 20 1) Material and Methods A random mutagenesis library was created on the chosen mutant, by PCR using Mn2+ or derivatives of dNTPs as 8-oxo-dGTP and dPTP in two-step PCR process as described in the protocol from JENA BIOSCIENCE GmbH in JBS dNTP Mutageneis kit. Primers used are: preATGCreFor (5' 25 gcataaattactatacttctatagacacgcaaacacaaatacacagcggccttgccacc-3'; SEQ ID NO: 103) and WO 2008/102274 PCT/IB2008/001334 51 ICreIpostRev (5'-ggctcgaggagctcgtctagaggatcgctcgagttatcagtcggccgc- 3 '; SEQ ID NO: 104). The new libraries were cloned in vivo in the yeast in the linearized kanamycin vector harbouring a galactose inducible promoter, a KanR as selectable marker and a 2 micron origin of replication. Positives resulting clones were verified by sequencing 5 (MILLEGEN). Pools of mutants were amplified by PCR reaction using these primers common for leucine vector (pCLS0542, Figure 13) and kanamycin vector (pCLS 1107, Figure 14). Approximately 75ng of PCR fragment and 75ng of vector DNA (pCLS 1107) linearized by digestion with DraIII and NgoMIV are used to transform 10 the yeast Saccharomyces cerevisiae strain FYC2-6A (MATcL, trplA63, leu2Al, his3A200) using a high efficiency LiAc transformation protocol. A library of intact coding sequence for the I-Crel mutant is generated by in vivo homologous recombination in yeast. Mutant-target yeasts are prepared and used as target for mating 15 assays as described in example 5. 2) Results: The mutants cleaving B2M 11.3 (I-Crel 28K30Q32S33G38C40S44Q68N70S75N77R also called KQSGCS/QNSNR according to nomenclature of Table III) was randomly mutagenized and transformed 20 into yeast. 6696 transformed clones were then mated with a yeast strain that (i) contains the B2M 11 target in a reporter plasmid (ii) expresses a optimized variant cleaving the B2Ml 1.2 target, chosen among those described in example 5. Four such strains were used, expressing either the I-CreI 28K30N32A33H38Q40S44A68Y70S75Y77K/132V mutant, the I-Crel 25 28K30N32G33H38Q40S44A68Y70S75Y77K/2196R105A mutant, the 28K30N32G33H38Q40S44A68Y70S75Y77K/120G mutant, or the 28K30N32A33H38Q40S44A68Y70S75Y77K/2Y53R66C mutant (see Table V). One hundred and one clones were found to trigger cleavage of the B2Ml 1 target when mated with such yeast strain. In a control experiment, none of these clones was found 30 to trigger cleavage of B2M 11 without coexpression of the KQSGCS/QNSNR protein. It was concluded that 101 positives were containing proteins able to cleave B2Ml 1 WO 2008/102274 PCT/IB2008/001334 52 when forming heterodimers with KQSGCS/QNSNR. Examples of such heterodimeric mutants are listed in Table V. Examples of positives are shown on Figure 11. Table V : Combinations that resulted in cleavage of B2M 11 target Optimized Mutant Mutant B2M113* B2M11 B2M11.2* OptID target (SEQ ID NO: 25 to 28) cleavage -Crel 28K3e33G38C40S44068N70S77R19S72F + -Crel 28K3H33G38C4GS44368N73S77R3HL83Q87L + I-Crel 28K30Q33G38C40S44Q68N70S77R/43L1 1 7G + I-Crel 28K30033G38C40S44Q68N70S77R49A + I-Crel 28K30033G38C40S44Q68N70S77R50R1 07R + I-Crel 28K30Q33G38C40S44Q68N70S77R54L + -Crel 28K3CQ33G38C4rS44Q68N7eS77RJ56E + I.Crel I-Crel 28K30033G38C40S44Q68N70S77R57N 3L+ 32G33H44A68Y70S75Y77 -Crel 28K30Q33G38C40S44Q68N70S77R60 0563 T + K I-Crel 28K30033G38C40S44068N70S77R60NO~55l5 + /2196R1 OSA I-Crel 28K30Q33G38C40S44Q68N70S77R/64A + I-Crel 28K30Q33G38C40S44068N70S77R/64D69 + or I-Crel 28K30Q33G38C40S44068N70S77R/69E82E + -Crel 28K3e33G38C4lS44Q68N7lS77R69G + I-Crei I-Crel 28K30033G38C40S44Q68N70S77R721 G + 32A33H44A68Y70S75Y77 -Crel 28K30033G38C40S44Q68N7S77R731 + K I-Crel 28K30Q33G38C40S44Q68N7S77R7311 6 + /1 32V I-Crel 28K30Q33G38C40S44Q68N70S77R/11 3S + I-Crel 28K30Q33G38C40S44Q68N70S77R103S17 + or I-Crel 28K30033G38C40S44Q68N70S77R105A47 + -Crel 28K3CQ33G38C4rS44e68N7eS77Rl1ID + 1-Crel I-Crel 28K30033G38C40S44Q68N70S77R110OI D + 32A33H44A68Y70S75Y77 -Crel 28K30Q33G38C40S44Q68N70S77R11 ilL + K -Crel 28K3 O33G38C4pS44Q68N7S77R1113 61rP + 2Y53R66C I-Crel 28K30(33G38C4S44Q68N7oS77R cleve + 1-Crel 28K30Q33G38C40S44Q68N70S77R/1537 + Or I-Crel 28K30Q33G38C40S44Q68N70S77R/1L3Q8 + I-Crel 28K30Q33G38C40S44Q68N70S77R/11567 + -Crel I-Crel 28K30Q33G38C40S44Q68N70S77R/15 + 32G33H44A68Y70S75Y77 I-Crel 28K30Q33G38C40S44Q68N70S77R/157 + KI-Crel 28K30Q33G38C40S44Q68N70S77R/54L + /1 20G I-Crel 28K30Q33G38C40S44Q68N70S77R/8G94Y + I-Crel 28K30Q33G38C40S44Q68N70S77R/8T83A17G + I-Crel 28K30Q33G38C40S44Q68N70S77R/891659Q + I-Crel 28K30Q33G38C40S44Q68N70S77R/182E107R + I-Crel 28K30Q33G38C40S44Q68N70S77R/85R + I-Crel 28K30Q33G38C40S44Q68N70S77R/87L + I-Crel 28K30Q33G38C40S44Q68N70S77R/92LG35P142R164G165P + I-Crel 28K30Q33G38C40S44Q68N70S77R/96R + I-Crel 28K30Q33G38C40S44Q 68Y70S77R/72T40M + I-Crel 28K30Q33G38S40S44Q68N70S77R + *+: indicates that the heterodimeric variant is cleaving the B2M1 1 target. 5 Optimized mutations are in bold Example 7: Making of meganucleases cleaving B2M11.2 in an extrachromosomic model in CHO cells with high efficacy by random mutagenesis of meganucleases cleaving B2M11.3 and co-expression with proteins cleaving B2M71. I-Crel mutants able to cleave the palindromic B2M 1 target with a 10 better efficiency have been identified in yeast by co-expression of mutants- optimized or not- cleaving palindromic B2M 11.2 and B2M 11.3 targets (Example 5). However, functional heterodimer in CHO cell are interesting and efficiency and number of positive combinations able to cleave B2M1 1 in mammalian cell cells using an extrachromosomal assay could be different than in yeast cell.
WO 2008/102274 PCT/IB2008/001334 53 Therefore the best proteins cleaving B2M 11.2 were mutagenized as in example 5, and variants cleaving with good efficiency B2M 1 when combined to optimized mutants for B2M 11.3 were screened. According to the structure of the I CreI protein bound to its target, there is no contact between the residues used for the 5 first combinatorial approach (28, 30, 32, 33, 38 and 40 vs 44, 68, 70, 75 and 77) in the I-Crel protein (Chevalier et al., Nat. Struct. Biol., 2001, 8, 312-316; Chevalier B.S. and Stoddard B.L., Nucleic Acids Res., 2001, 29, 3757-3754; Chevalier et al., J. Mol. Biol., 2003, 329, 253-269). Thus, it is difficult to rationally choose a set of positions to mutagenize, and mutagenesis was done on the C-terminal part of the protein (83 10 last amino acids) or on the whole protein. 1) Material and Methods a) Construction of libraries by random mutagenesis Random mutagenesis libraries on a pool of chosen mutants were created by PCR using Mn 2 + or derivatives of dNTPs as 8-oxo-dGTP and dPTP in two 15 step PCR process as described in the protocol from JENA BIOSCIENCE GmbH in JBS dNTP-Mutageneis kit. Primers used are attBI-ICreIFor (5' ggggacaagtttgtacaaaaaagcaggcttcgaaggagatagaaccatggccaataccaaatataacaaagagttcc-3': (SEQ ID NO: 120) and attB2-ICreIRev (5' ggggaccactttgtacaagaaagctgggtttagtcggccgccggggaggatttcttcttctcgc-3': SEQ ID NO: 20 121). PCR products obtained were cloned in vitro in CHO Gateway expression vector pCDNA6.2 from INVITROGEN (pCLS 1069, Figure 16). In parallel, chosen mutants used for libraries were cloned in the same way in this vector. Cloned mutants and positives resulting clones of libraries were verified by sequencing (MILLEGEN). b) Construction of B2M 11 target in a vector for screening in CHO cells 25 From yeast target vector (as example 1) the B2Mll target was amplified by two steps PCR using primers Mls (5'-aaaaagcaggctgattggcatacaagtt-3': SEQ ID NO: 122) and M2s (5'-agaaagctgggtgattgacagacgattg-3': SEQ ID NO: 123) followed by attBladapbis (5'-ggggacaagtttgtacaaaaaagca-3': SEQ ID NO: 124) and attB2adapbis (5'- ggggaccactttgtacaagaaagct-3': SEQ ID NO: 125). Primers are from 30 PROLIGO. Final PCR was cloned using the Gateway protocol (INVITROGEN) into CHO reporter vector (pCLS1058, Figure 17). Cloned target was verified by sequencing (MILLEGEN).
WO 2008/102274 PCT/IB2008/001334 54 c) Extrachromosomal assay in mammalian cells CHO cells were transfected with Polyfect transfection reagent according to the supplier's protocol (QIAGEN). 72 hours after transfection, culture medium was removed and 150 pl of lysis/revelation buffer added for P-galactosidase 5 liquid assay (typically, 1 liter of buffer contained 100 ml of lysis buffer (Tris-HCl 10 mM pH7.5, NaCl 150 mM, Triton X100 0.1%, BSA 0.1 mg/ml, protease inhibitors), 10 ml of Mg 1OOX buffer (MgCl 2 100 mM, P-mercaptoethanol 35 %), 1 Oml ONPG 8 mg/ml and 780 ml of sodium phosphate 0.1M pH7.5). After incubation at 37 *C, optical density (OD) was measured at 420 nm. The entire process was performed on 10 an automated Velocityl1 BioCel platform. Per assay, 150 ng of target vector was cotransfected with 12.5 ng of each one of both mutants (12.5 ng of mutant cleaving palindromic B2Ml1.2 target and 12.5 ng of mutant cleaving palindromic B2M11.3 target) 2) Results 15 The optimized mutants cleaving B2M 11.2 (I-CreI 32G33H44A68Y70S75Y77K/120G, 32A33H44A68Y70S75Y77K/2Y53R66C, 32G33H44A68Y70S75Y77K/2I96R105A and 32A33H44A68Y70S75Y77K/132V as described into Table V) were randomly mutagenized and transformed into Gateway vector (Figure 16). DNA plasmid of 1920 transformed clones were purified and then 20 cotransfected with the CHO B2M 11 target vector and an optimized variant cleaving the B2M1 1.3 target, chosen among those described in example 6. Cotransfection of the transformed clones with the CHO B2M 11 target vector and the initial mutant (30Q33G38C68N70S77R) cleaving B2M1 1.3 was included for comparison. Sixty clones were found to trigger cleavage of the B2M 11 target when co-transfected with 25 an optimized variant cleaving B2M 11.3 target. In a control experiment, none of these clones was found to trigger cleavage of B2M 11 without cotransfection of a (optimized or not) variant cleaving the B2M 11.3 target. It was thus concluded that 60 positives were containing proteins able to cleave B2M 11 when forming heterodimers with optimized variant cleaving the 30 B2M 11.3 target. Examples of such heterodimeric mutants derived from two optimized variants cleaving the B2M11.3 target (30Q33G38C68N70S77R/43L115T117G and 30Q33G38C68N70S77R/110D) are listed in Table VI.
WO 2008/102274 PCT/1B2008/001334 55 Table VI: Combinations that resulted in cleavage* of the B2M11 target in CHO cells. Initial (30Q33G38C68N70S77R) and CHO Optimized Mutants 132M11.2 Optimized B2MII1.3 mutants Optimized Optimized Initial 43L115T117G 110D 32A33H44A68Y70S75Y77K/1 32V ++ 32A33H44A68Y70S75Y77K/1 9S1 20G nd 32A33H44A68Y70S75Y77K119S1 32V ++ + + 32A33H44A68Y70S75Y77K119S43L + + 1 32A33H44A68Y70S75Y77K/1 9S43L53R66C ++- 1 32A33H44A68Y70S75Y77K/24F1 1 7G + 1 + 32A33H44A68Y70S75Y77K/43L1 32V ++1 + 32G33H44A68Y70S75Y77K/ 1 32G33H44A68Y70S75Y77K/1 05A + - + 32G33H44A68Y70S75Y77K/1 05A1 28R+-- 32G33H44A68Y70S75Y77K/1 05A1 62F+1 32G33H44A68Y70S75Y77K/1 1 7G 1654G+1+- 32G33H44A68Y70S75Y77K/1 20G+1+- 32G33H44A68Y70S75Y77K1 20G1 62F+-- 32G33H44A68Y70S75Y77K/1 20G1 63Q -- 32G33H44A68Y70S75Y77K/119S431105A ++- + 32G33H44A68Y70S75Y77K/119S96R1 05A nd- 1 32G33H44A68Y70S75Y77K/24F89A1 17GI 62F1 65P + ++1 32G33H44A68Y70S75Y77K2196R1 05A- - 32G33H44A68Y70S75Y77K14Q96R1 05A+-- 32G33H44A68Y70S75Y77K179G96R1 05A+-- 32G33H44A68Y70S75Y77K/89A 1- 32G33H44A68Y70S75Y77K/89120G -- 32G33H44A68Y70S75Y77K/92R96R1 05A -- 32G33H44A68Y70S75Y77K/94L1 05A+-- 32G33H44A68Y70S75Y77K/96R1 QOQi 05A1 61 F -- 32G33H44A68Y70S75Y77K196R1 05A ++- + 32G33H44A68Y70S75Y77K196R 1 05A1 1 7G +/- *(-):< 0.25. (±): 0.25 !9 < 0,5. (+) :0,5 !9 < 1,2. (++): : 1,2. Values (absorbance unit) 5 correspond to average of experimental results of the extrachromosomal assay in CHO cells WO 2008/102274 PCT/IB2008/001334 56 Example 8: Making of meganucleases cleaving B2M18. Two news series of palindromic targets, B2MI8.3 and B2M18.4 were derived from B2M18 and B2M20.3 and B2M20.4 from B2M20 (Figures 18 and 21). Since B2M18.3, B2M18.4, B2M20.3 and B2M20.4 are palindromic, they should 5 be cleaved by homodimeric proteins. First, proteins able to cleave the B2M18.4 sequence as homodimers were designed (example 8), and then proteins able to cleave the B2M20.4 sequences as homodimers were designed (example 9). This example shows that I-Crel variants can cleave the B2M18.4 DNA target sequence derived from the right part of the B2M 18 target in a palindromic 10 form (Figure 18). All target sequences described in this example are 22 bp palindromic sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix _P. For example, B2M18.4 will be called TTAACTATCGTP (SEQ ID NO: 113). B2M18.4 is similar to 5ATCP in positions +1, +2, +3, +4, +5, +8 15 and +9 and to 1OTAAP in positions ±1, +2, ±3, ±4, +8, ±9 and +10. It was hypothesized that positions ±6, +7 and ± 11 would have little effect on the binding and cleavage activity. Mutants able to cleave 5ATCP target (CAAAACATCGTP) were previously obtained by mutagenesis on I-Crel N75 at positions 44, 68, 70, 75 and 77, as described in Arnould et al., J. Mol. Biol., 2006, 355, 443-458 and International 20 PCT Applications WO 2006/097784, WO 2006/097853. Mutants able to cleave the 5ATCP target (CTAAACGTCGTP) were obtained by mutagenesis on I-Crel N75 and D75 at positions 28, 30, 32, 33, 38, 40 and 70 as described in Smith et al., Nucleic Acids Res., 2006, 34, e149 . Thus combining such pairs of mutants would allow for the cleavage of the B2M18.4 target. 25 Both sets of proteins are mutated at position 70. However, the existence of two separable functional subdomains was hypothesized. That implies that this position has little impact on the specificity in base 10 to 8 of the target. Therefore, mutations at positions 44, 68, 70, 75 and 77 from proteins cleaving 5ATC_P (CAAAACATCGTP) were combined with the 28, 30, 32, 33, 38, 40 mutations from 30 proteins cleaving 10TAAP (CTAAACGTCGTP) to check whether combined mutants could cleave the B2M18.4 target.
WO 2008/102274 PCT/IB2008/001334 57 1) Material and Methods The experimental procedure is as described in example 2. 2) Results I-CreI combinatorial mutants were constructed by associating 5 mutations at positions 44, 68, 70, 75 and 77 with the 28, 30, 33, 38 and 40 mutations on the I-CreI N75 or D75 scaffold, resulting in a library of complexity 1600. Examples of combinatorial mutants are displayed on Table VII. This library was transformed into yeast and 3348 clones (2.1 times the diversity) were screened for cleavage against B2M18.4 DNA target (TTAACTATCGTP). 59 positives clones 10 were found, which after sequencing and validation by secondary screening turned out to be correspond to 18 novel endonucleases (SEQ ID NO: 136 to 152 and 179; see Table VII). Positives are shown in Figure 19. One positive clone presents an additional mutation in position 153. The sequence of this clone is KNRTQS/ QYSRQ - 153G. Table VII : Cleavage of the B2M18.4 target by the combinatorial mutants* Amino acids at Amino acids at positions 28, 30, 32, 33, 38 and 40 (ex: KHSCQS stands for positions 44, 68, K28, H30, S32, C33, Q38 and S40) 70, 75 and 77 (ox: QYSRQ KHSCQS KNGCQS KNSCQQ KNACQS KNGSQS KNRTQS stands for Q44, Y68, S70, R75 and Q77) QYSRQ + + + TYSRI QNSNR QASRI QRSRI NYSRQ + + + NYSRV + + + + TYSRS TYSRV NYSRH QRSNK TYSRQ + + QRRNI QQSAR RYSYT QYSRV + RYSRQ + QYSRI + QQSNR SYSRI NYSRY + + QQSRI NTSRV QRPNI
HASRY
WO 2008/102274 PCT/IB2008/001334 58 * Only 138 out of the 1600 combinations theoretically present in the combinatorial library are displayed. + indicates that the combinatorial mutant was found among the identified positives. Example 9: Making of meganucleases cleaving B2M20 This example shows that I-Crel variants can cleave the B2M20.4 5 DNA target sequence derived from the right part of the B2M20.1 target in a palindromic form (Figure 19). All target sequences described in this example are 22 bp palindromic sequences. Therefore, they will be described only by the first 11 nucleotides, followed by the suffix _P. For example, B2M20.4 will be called TTACATGTCGTP: SEQ ID NO: 119). 10 B2M18.4 is similar to 5GTCP in positions ±1, ±2, +3, +4, +5 and +7 and to 1OTACP in positions ±1, +2, ±3, +4, +5, ±7,±8, +9 and ±10. It was hypothesized that positions +6 and +11 would have little effect on the binding and cleavage activity. Mutants able to cleave 5GTCP target (CAAAACGTCGTP) were previously obtained by directed mutagenesis on I-Crel at positions 70 and 75 as 15 described in Amould et al., J. Mol. Biol., 2006, 355, 443-458 and International PCT Applications WO 2006/097784, WO 2006/097853. Mutants able to cleave the 1 OTACP target (CTACACGTCGTP) were obtained by mutagenesis on I-CreI N75 and D75 at positions 28, 30, 32, 33, 38, 40 and 70, as described in Smith et al., Nucleic Acids Res., 2006, 34, e149. Thus combining such pairs of mutants would 20 allow for the cleavage of the B2M20.4 target. Both sets of proteins are mutated at position 70. However, the existence of two separable functional subdomains was hypothesized. That implies that this position has little impact on the specificity in base 10 to 8 of the target. Therefore, mutations at positions 70 and 75 from proteins cleaving 5GTC_P 25 (CAAAACGTCGTP) were combined with the 28, 30, 32, 33, 38, 40 mutations from proteins cleaving 10TACP (CTACACGTCGTP) to check whether combined mutants could cleave the B2M20.4 target. 1) Material and Methods The experimental procedure is as described in example 2. 30 2) Results I-Crel combinatorial mutants were constructed by associating mutations at positions 70 and 75 with the 28, 30, 33, 38 and 40 mutations on the I CreI N75 or D75 scaffold, resulting in a library of complexity 1536. Examples of WO 2008/102274 PCT/IB2008/001334 59 combinatorial mutants are displayed on Table VIII. This library was transformed into yeast and 6696 clones (4.4 times the diversity) were screened for cleavage against B2M20.4 DNA target (TTACATGTCGTP). 196 positives clones were found, which after sequencing and validation by secondary screening turned out to be correspond to 5 164 novel endonucleases (see Table VIII showing SEQ ID NO: 153 to 178). Positive is shown in Figure 21. 12 clones present additional mutations (56G, 82R, 147A or 161F), as in example 8. Table VIII : Cleavage of the B2M20.4 target by the combinatorial mutants* Amino acids Amino acids at positions 70 and 75 at positions (e: SN stands for S70 and 75) 28, 30, 32, 33, 38 and 40 (ex: ANSSQR stands for A28, N30, S32, S33, SN SY RN RA SA RY SE RE SD RD Q38 and R40) ANSSQR + ANSTQR + RNSAYQ + RNSNRQ + RNSRYQ + RNSSRQ + RNSSYQ + TNSNQD + TNSTQR + KNGCQS + KNSCQS + KNSSQR + + KASGQS + KASTQS + KCSAQS + KCSCQS + KSSSTS + KTWYQS + KHSKQS + KRSPQS + KKSTQS + KPSWQS + KNGPQS + KNTAQS + KNSTQE + 10 * Only 230 out of the 1536 combinations theoretically present in the combinatorial library are displayed. + indicates that the combinatorial mutant was found among the identified positives.
Claims (1)
- 28. 310) The use of at least one variant of anyone of claims I to 13, one single-chain chimeric meganuclease of claim 14 or claim 15, and/or one expression 5 vector of anyone of claims 17 to 28, for the preparation of a medicament for preventing, improving or curing xenograft rejection during cell transplantation from a donor individual into a recipient individual in need thereof. 320) The use of claim 31, wherein said transplantation is kidney, pancreas, muscle or heart cell transplantation. 10 330) The use of at least one variant of anyone of claims 1 to 13, one single-chain chimeric meganuclease of claim 14 or claim 15, and/or one expression vector of anyone of claims 17 to 28, for the preparation of a medicament for preventing, improving or curing a pathological condition associated with a fibrillar conformation of the beta-2 microglobulin in an individual in need thereof. 15 340) A host cell which is modified by a polynucleotide of claim 16 or a vector of anyone of claims 17 to 28. 35) A non-human transgenic animal comprising one or two polynucleotide fragments as defined in claim 16 or claim 18. 360) A transgenic plant comprising one or two polynucleotide 20 fragments as defined in claim 16 or claim 18. 37*) Use of at least one variant of anyone of claims 1 to 13, one single-chain chimeric meganuclease of claim 14 or claim 15, one vector according to anyone of claims 17 to 28, for genome engineering, for non-therapeutic purposes. 380) The use of claim 36, wherein said variant, single-chain 25 chimeric meganuclease, or vector is associated with a targeting DNA construct as defined in anyone of claims 19 to 28. 390) The use of claim 38, wherein said targeting DNA construct comprises an exogenous gene of interest, and eventually a marker gene, flanked by sequences uptstream an downstream the beta-2 microglobumin locus, to allow 30 replacement of the beta-2 microglobulin gene by the exogenous gene of interest. 400) The use of anyone of claims 37 to 39, for making a transgenic animal or a recombinant cell line expressing an heterologous protein of interest. WO 2008/102274 PCT/IB2008/001334 67 410) The use of claims 40, wherein said recombinant cell line is a human recombinant cell line.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPCT/IB2007/001532 | 2007-02-20 | ||
PCT/IB2007/001532 WO2008102199A1 (en) | 2007-02-20 | 2007-02-20 | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
PCT/IB2008/001334 WO2008102274A2 (en) | 2007-02-20 | 2008-02-20 | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2008218605A1 true AU2008218605A1 (en) | 2008-08-28 |
Family
ID=39167465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008218605A Abandoned AU2008218605A1 (en) | 2007-02-20 | 2008-02-20 | Meganuclease variants cleaving a DNA target sequence from the beta-2-microglobulin gene and uses thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2121036A2 (en) |
JP (1) | JP2010518832A (en) |
CN (1) | CN101678126A (en) |
AU (1) | AU2008218605A1 (en) |
CA (1) | CA2678709A1 (en) |
WO (2) | WO2008102199A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2215223B1 (en) * | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
WO2009114321A2 (en) | 2008-03-11 | 2009-09-17 | Precision Biosciencs, Inc. | Rationally-designed meganucleases for maize genome engineering |
CA2730921A1 (en) | 2008-07-14 | 2010-01-21 | Precision Biosciences, Inc. | Recognition sequences for i-crei-derived meganucleases and uses thereof |
WO2010026443A1 (en) * | 2008-09-08 | 2010-03-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof |
WO2010122367A2 (en) * | 2009-04-21 | 2010-10-28 | Cellectis | Meganuclease variants cleaving the genomic insertion of a virus and uses thereof |
WO2010136841A2 (en) * | 2009-05-26 | 2010-12-02 | Cellectis | Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof |
US20120171191A1 (en) | 2009-05-26 | 2012-07-05 | Cellectis | Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof |
WO2011007193A1 (en) | 2009-07-17 | 2011-01-20 | Cellectis | Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting |
WO2011021062A1 (en) | 2009-08-21 | 2011-02-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof |
EP2569424A1 (en) | 2010-05-12 | 2013-03-20 | Cellectis | Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
US20130183282A1 (en) | 2010-05-12 | 2013-07-18 | Cellectis | Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof |
EP2580336B1 (en) | 2010-06-09 | 2017-05-10 | Bayer CropScience NV | Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering |
CN103119169B (en) | 2010-06-09 | 2018-11-20 | 拜尔作物科学公司 | Plant Genome transformation in commonly on nucleotide sequence modified plant genome Method and kit for |
WO2012001527A2 (en) | 2010-06-15 | 2012-01-05 | Cellectis S.A. | Method for improving cleavage of dna by endonuclease sensitive to methylation |
US20130189759A1 (en) | 2010-07-07 | 2013-07-25 | Cellectis | Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof |
WO2012010976A2 (en) | 2010-07-15 | 2012-01-26 | Cellectis | Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof |
WO2012007848A2 (en) | 2010-07-16 | 2012-01-19 | Cellectis | Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof |
US20130337454A1 (en) | 2010-10-27 | 2013-12-19 | Philippe Duchateau | Method for increasing the efficiency of double-strand break-induced mutagenesis |
WO2012138901A1 (en) | 2011-04-05 | 2012-10-11 | Cellectis Sa | Method for enhancing rare-cutting endonuclease efficiency and uses thereof |
CA2832534C (en) | 2011-04-05 | 2022-01-04 | Julien Valton | Method for the generation of compact tale-nucleases and uses thereof |
WO2012158778A1 (en) | 2011-05-16 | 2012-11-22 | Cellectis S.A. | Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems |
EP2729567B1 (en) | 2011-07-08 | 2016-10-05 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenssis |
CN104046593A (en) * | 2013-03-14 | 2014-09-17 | 浙江大学 | Human cell with low immunogenicity and preparation method thereof |
WO2014165825A2 (en) * | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
EP3116902B1 (en) * | 2014-03-11 | 2020-01-01 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
JP7033453B2 (en) * | 2015-06-30 | 2022-03-10 | セレクティス | How to Improve NK Cell Functionality by Gene Inactivation Using Specific Endonucleases |
US10799535B2 (en) | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
MX2018004146A (en) | 2015-10-05 | 2018-11-09 | Prec Biosciences Inc | Genetically-modified cells comprising a modified man t cell receptor alpha constant region gene. |
EA201891212A1 (en) * | 2015-12-18 | 2019-01-31 | Сангамо Терапьютикс, Инк. | ADDRESS DISORGANIZATION OF GKGS CELL RECEPTOR |
ES2901000T3 (en) | 2015-12-23 | 2022-03-21 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
BR112019020203A2 (en) | 2017-03-31 | 2020-06-02 | Cellectis Sa | MODIFIED UNIVERSAL IMMUNE CELLS OF THE ANTI-CD22 CHEMICAL ANTIBODY RECEPTOR |
US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
WO2019097083A1 (en) * | 2017-11-20 | 2019-05-23 | Tessa Therapeutics Pte. Ltd. | Modified k562 cell |
WO2019200122A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
CA3117709A1 (en) * | 2018-10-25 | 2020-04-30 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for selecting biallelic gene editing |
KR20210148293A (en) | 2019-04-03 | 2021-12-07 | 프리시젼 바이오사이언시스 인코포레이티드 | Gene-modified immune cells containing microRNA-adapted shRNAs (shRNAmiRs) |
CN114026228A (en) * | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | Optimization of engineered meganucleases for recognition sequences |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN115475247B (en) * | 2021-06-16 | 2024-02-20 | 厦门大学 | Pharmaceutical use of beta 2-microglobulin or inhibitor thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153826A1 (en) * | 2003-01-28 | 2006-07-13 | Sylvain Arnould | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
WO2006097784A1 (en) * | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
SG10201508995QA (en) * | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
-
2007
- 2007-02-20 WO PCT/IB2007/001532 patent/WO2008102199A1/en active Application Filing
-
2008
- 2008-02-20 CA CA002678709A patent/CA2678709A1/en not_active Abandoned
- 2008-02-20 EP EP08751044A patent/EP2121036A2/en not_active Withdrawn
- 2008-02-20 AU AU2008218605A patent/AU2008218605A1/en not_active Abandoned
- 2008-02-20 CN CN200880005471A patent/CN101678126A/en active Pending
- 2008-02-20 JP JP2009550342A patent/JP2010518832A/en active Pending
- 2008-02-20 WO PCT/IB2008/001334 patent/WO2008102274A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2010518832A (en) | 2010-06-03 |
WO2008102199A1 (en) | 2008-08-28 |
WO2008102274A3 (en) | 2009-02-12 |
WO2008102274A2 (en) | 2008-08-28 |
EP2121036A2 (en) | 2009-11-25 |
CN101678126A (en) | 2010-03-24 |
CA2678709A1 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8426177B2 (en) | Meganuclease variants cleaving a DNA target sequence from the mouse ROSA26 locus and uses thereof | |
AU2008218605A1 (en) | Meganuclease variants cleaving a DNA target sequence from the beta-2-microglobulin gene and uses thereof | |
US20110091441A1 (en) | Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof | |
US20090271881A1 (en) | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof | |
US20100203031A1 (en) | Method for enhancing the cleavage activity of i-crei derived meganucleases | |
US20090222937A1 (en) | Meganuclease variants cleaving a dna target sequence from a xeroderma pigmentosum gene and uses thereof | |
AU2008278705A1 (en) | Meganuclease variants cleaving a DNA target sequence from the human hemoglobin beta gene and uses thereof | |
WO2009001159A1 (en) | Method for enhancing the cleavage activity of i-crei derived meganucleases | |
US20110041194A1 (en) | I-msoi homing endonuclease variants having novel substrate specificity and use thereof | |
WO2011021062A1 (en) | Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |